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ABSTRACT

EPIGENETIC MODIFICATIONS ASSOCIATED WITH AORTIC
REMODELING IN HYPERHOMOCYSTEINEMIA
Nithya Narayanan
April 16, 2014

Background: Hyperhomocysteinemia (HHcy) is prevalent in hypertensive patients and is
an independent risk factor for aortic pathologies. HHcy is known to cause an imbalance
between matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases
(TIMPs) leading to accumulation of collagen in the aorta resulting in stiffness and
development of hypertension. Although the exact mechanism of extracellular matrix
remodeling (ECM) is unclear, emerging evidence implicates epigenetic regulation
involving DNA methylation. The purpose of the study was to investigate whether
inhibition of DNA methylation reduces high blood pressure by regulating aortic ECM
remodeling in HHcy.
Methods: In the first set of experiments, we studied the effect of HHcy in causing
epigenetic changes leading to aortic remodeling resulting in hypertension. Cystathionine
beta synthase heterozygous knockout (CBS+/-) mice of C57BL/6J background were used
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as HHcy model and their Wild type (WT) littermates were used as controls. Hcy level in
plasma was measured by HPLC-UV. Blood pressure was measured using tail-cuff
method. The mRNA expression levels of ECM proteins and epigenetic modifications
enzymes in the aorta were measured by RT-PCR. Global methylation level was measured
by ELISA.
In the second set of experiments, we studied effects of an epigenetic DNA
methyltransferase inhibitor, 5-Aza-2’-deoxycytidine (Aza) in HHcy. For in vivo studies,
we used 8-12 weeks old WT and CBS+/- mice and administered them with Aza for four
weeks. During the treatment period, blood pressure was measured using tail-cuff method.
Aorta wall thickness, lumen diameter and resistive index were measured before and after
treatment using ultrasound. Aortic responses to vasoconstrictor and vasodilators were
measured using tissue myobath. Collagen accumulation in the aortic walls was measured
by Mason Trichrome and Picrosirius red staining. ECM proteases, Hcy metabolism
enzymes and DNMT1 expression were measured using immunostaining. Global
methylation levels were assessed using ELISA. For cell culture studies, mouse aortic
smooth muscle cells were treated with Aza and Hcy for 48 hrs. MMP9 activity was
measured using gelatin zymography and DNMT1, 3a and 3b expression was measured
using immunoblotting.
Results: In CBS+/- mice, increased plasma Hcy levels were associated with an increase
in blood pressure. There was an increase in the mRNA levels of collagen and decrease in
elastin in HHcy mice. Global hypermethylation was accompanied by an increased
expression of methylation proteins in HHcy. Aza treatment normalized plasma SAM,
SAH and Hcy levels and blood pressure in HHcy mice. Thoracic and abdominal aorta
vii

ultrasound revealed reduction in resistive index and wall-to-lumen ratio. Vascular
response to vasoactive agents improved following Aza treatment in HHcy. Histology
showed a marked reduction in collagen deposition in the aorta. Aza treatment decreased
the expression of DNMT1, 3b, MMP9, TIMP1 and S-adenosyl homocysteine hydrolase
(SAHH) and upregulated methylene tetrahydrofolate reductase (MTHFR)
Conclusion: We conclude that reduction of DNA methylation in HHcy reduces adverse
aortic remodeling to mitigate hypertension.
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CHAPTER I
INTRODUCTION
Cardiovascular diseases cause to about 13.4 million deaths annually worldwide
and are a major global economic concern [1, 2]. Although arterial diseases are not the
most common of the cardiovascular diseases (CVD), they cause 3.4% of deaths due to
CVD (Figure 1) [3]. Data from the Centers for Disease Control and Prevention (CDC)
state that diseases of the aorta and its branches account for 43,000 to 47,000 deaths
annually in the United States [4]. Many risk factors including age, lifestyle, hypertension
and elevated plasma homocysteine (Hcy) levels contribute to the occurrence of aortic
diseases.
Homocysteine (Hcy) is a non-protein forming, non-essential amino acid that is an
intermediate in methionine metabolism. Plasma Hcy levels varies between individuals
and elevated plasma Hcy (hyperhomocysteinemia, HHcy), is associated with increased
risk of CVD. In 2004, Giusti et al., report an increase in total plasma Hcy levels in
patients with aortic dissection and abdominal aortic aneurysm [5]. The biological effects
of HHcy relevant to aortic diseases include increased oxidative stress, pro – inflammatory
effects, impaired endothelial function, altered lipid metabolism and extracellular matrix
remodeling. [6-9]
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Extracellular matrix (ECM) provides physical support and triggers various
signaling pathways within all tissues and organs. The production of ECM proteins such
as collagen, or proteases such as matrix metalloproteinases (MMPs) and their inhibitors,
tissue inhibitors of metalloproteinases (TIMPs) play a crucial role in determining the
structure and function of the aorta. In aortic diseases, the balance between expressions of
different ECM components is disrupted, leading to remodeling.
Emerging evidence suggests that epigenetic modifications play an important role
in controlling a wide spectrum of biological processes. DNA methylation regulates gene
expression during fetal reprogramming and contributes to the development of an
extensive range of chronic pathologies. DNA methylation is facilitated by the enzyme,
DNA methyltransferase (DNMT) that catalyze the transfer of a methyl group to
previously unmethylated DNA. Several studies suggest that changes in epigenetic
modifications can be caused by age, environmental factors/lifestyle, or various diseases
[10-13]. Hence, the US Food and Drug Administration has approved drugs that
specifically target epigenetic modifications such as DNA methylation and histone
modification molecules which are currently in therapeutic use for diseases such as stroke
and cancer [14, 15]. Nevertheless, it is unknown whether epigenetic inhibitors have a
therapeutic role in HHcy-induced hypertension. In the current study, we examined the
epigenetic modifications involved in aortic ECM remodeling in HHcy induced
hypertension and the effect of a DNMT1 inhibitor in mitigating this condition.
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Figure 1: Percentage breakdown of deaths attributable to cardiovascular diseases
(United States: 2010). Source: National Heart, Lung, and Blood Institute from National
Center for Health Statistics reports and data sets.
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CHAPTER II
BACKGROUND
Aortic diseases
The aorta, which is the largest artery in the body, supplies oxygenated blood from
the left ventricle to systemic circulation. The aorta can be divided into different sections
based on areas that its branching arteries supply: the ascending aorta supplies blood to the
heart, the arch of the aorta supplies the head, neck and arms, and the descending aorta
supplies the lower half of the body (Table 1). A study of the thoracic aortic diameters
using computed tomography reveals that the diameter of the ascending aorta is larger
than the diameter of the descending thoracic aorta and the aorta in a normal healthy adult
dilates with age at a rate of 0.1cm per decade [16]. The aorta is composed of three tunics
or layers: the intima, media and adventitia. The innermost layer or intima consists of a
layer of squamous endothelial cells, an acid mucopolysaccharide rich extracellular matrix
composed of fibroblasts and macrophages, and elastic lamella. The media comprises of
elastic fiber rings separated by layers of collagen and elastin fibers with undifferentiated
smooth muscle cells. The concentric elastic lamellae contribute to the radial strength and
elasticity of the aorta. The outermost layer or adventitia, consists of a thin collagen rich
layer of fibroblasts, smooth muscle cells and vasa vasorum. Vasa vasorum are a network
of arterioles that provide a vascular supply to the aorta [17]. Aortic diseases can be
classified as aortic valve diseases such as those that affect the bicuspid aortic valve, or
4

aortic disorders due to changes in its wall composition such as atherosclerosis, aortic
aneurysm and aortic dissection.

Aorta
Ascending aorta

Branches
Coronary arteries

Arch of the aorta

Innominate
Left common carotid
Left subclavian

Descending aorta
Thoracic aorta

Abdominal aorta

Visceral – Pericardial, Bronchial, Esophageal,
Mediastinal
Parietal – Intercostal, Subcostal, Superior phrenic
Visceral – Celiac, Superior mesenteric, Inferior
mesenteric, Middle suprarenals, Renals, Internal
spermatics, Ovarian (in females)
Parietal – Inferior phrenics, Lumbars, Middle sacral
Terminal – Common iliacs

Table 1: The aorta and its branches
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Bicuspid aortic valves
Bicuspid aortic valves are characterized as two unequally sized leaflets instead of
the normal tricuspid aortic valve [18]. This congenital abnormality is most commonly
identified as a systolic ejection click during exam. It is present in about 1-2% of the
population and the anomaly often has no symptoms, although the coronary arteries may
be abnormal and sometimes the aortic root is dilated. A causal relationship between aortic
aneurysm and bicuspid aortic valves has been hypothesized [19].
Atherosclerosis
Atherosclerosis can affect any artery of the body. Aortic plaques are a common
feature of atherosclerosis which is found in elderly people. Plaques are formed due to
deposition of fat, cholesterol and calcium in the intimal layers of arteries. These plaques
harden and narrow the vessel diameter causing obstruction to blood flow. Plaques with
thickness ≥ 4 mm are termed severe plaques and are susceptible to embolization. The
plaque can disintegrate, forming a blot clot and can result in pathophysiological
complications such as heart attack, stroke and peripheral artery diseases. Some risk
factors associated with atherosclerosis are hypertension, hypercholesterolemia, age,
smoking, diabetes, increased levels of homocysteine, thrombotic diathesis markers such
as prothrombin and activated protein C resistance, and inflammatory markers like white
blood cell count and C-reactive protein [20-24]

6

Aortic aneurysm
An aneurysm is an abnormal, irreversible dilation caused by weakness due to a
decrease in elastin in the arterial wall. Abdominal aortic aneurysms (AAA) are known to
be associated with atherosclerosis, hypertension, hyperhomocysteinemia and smoking
[25-28]. The most common site for an aneurysm to develop is in the abdominal aorta.
Most AAA occurs below the level of the renal arteries. They may affect the bifurcation
of the aorta as well as the iliac arteries. Aneurysms often increase in size; they can
rupture and lead to hemorrhage and even death. If an aneurysm is greater than 5 cm,
surgery is generally recommended. In the descending thoracic and abdominal aorta,
aneurysms result from severe intimal atherosclerosis, increased elastin and collagen
degrading enzymes and pro-inflammatory cytokines, chronic inflammation, and
remodeling of the elastic media [5]. Important risk factors of aortic aneurysm include
cigarette smoking, age, gender, hypertension and elevated levels of homocysteine [29].
Thoracic aortic aneurysms (TAA), like AAA, are caused due to atherosclerosis,
trauma, and hypertension. Other unique factors which have been found to play a major
role in causing TAA are syphilis [30], Marfan syndrome (MFS), and bicuspid aortic
valves. Aneurysms in the ascending aorta are due to degeneration of the aortic media by
cystic medial necrosis (CMN): loss of smooth muscle cells and degeneration of elastic
fibers. Accelerated CMN has been known to be associated with genetic syndromes, like
MFS [5]
MFS is an autosomal dominant condition affecting connective tissue that is
characterized by skeletal, ocular, and cardiovascular problems.
7

MFS patients have

thoracic aortic aneurysms and dissections (TAA/TAD) as well as valvular abnormalities,
like bicuspid aortic valve [31]. CMN in MFS patients may be caused by abnormal
fibrillin-1 which is a part of the elastic fiber that surrounds an elastin core. This results in
a weakened aortic wall due to loss of intact elastin.
Aortic Dissection
Dissection is a condition which is distinct from aneurysm and may affect the
thoracic or abdominal aorta. An intimal tear leads to separation of layers of the aortic
wall and forms a passageway for blood flow. This diverts blood flow throughout the aorta
in the chest and abdomen and results in ischemia [32].
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Homocysteine
Homocysteine (Hcy) is a non-protein coding amino acid derived from dietary
methionine. In the plasma, 70% of Hcy is bound to albumin, 1% exists as free thiols and
the remainder is bound to cysteine by disulfide linkages, or as Hcy dimers. Dietary
methionine gets activated by adenosine triphosphate (ATP) and three isoenzymes of
methionine adenosyl triphosphate (MAT I, II and III) to form S-adenosyl methionine
(SAM), a universal methyl donor. The methyl group of SAM is activated by the positive
charge of its sulfur atom and gets removed from SAM to form S-adenosyl homocysteine
(SAH). This highly reactive methyl group methylates various substrates such as proteins,
RNA, phospholipids, myelin, catecholamines, polysaccharides, creatine, carnitine and
DNA. SAH is hydrolyzed by SAH hydrolase (SAHH), in a reversible reaction, to yield
Hcy. Total plasma Hcy levels are sometimes denoted as tHcy. Normal plasma Hcy levels
in humans are between 5 and 15µM [33].
Hcy gets metabolized through two pathways – trans-sulfuration and remethylation
(Figure 2). In most tissues, Hcy is remethylated to methionine by vitamin B12 dependent
methionine synthase (MS). MS uses a methyl group from the de-methylation of methyl
tetrahydrofolate (methyl THF). Methyl THF is one of the intermediates in the folate
metabolism pathway, which is synthesized from 5, 10 methylene-tetrahydrofolate
catalyzed by methylene tetrahydrofolate reductase (MTHFR). In liver and kidneys, Hcy
remethylation is carried out by betaine Hcy methyltransferase (BHMT). The
transsulfuration pathway is active in liver, kidney, small intestine and pancreas. Hcy
condenses with serine and gets converted to cystathionine in the presence of vitamin B6
activated enzyme, cystathionine beta synthase (CBS). Cystathionine is hydrolyzed by 
9

cystathionase to cysteine and α ketobutyrate. CBS removes Hcy from the methionine
cycle permanently by catalyzing the synthesis of cystathionine from Hcy and serine [34].
Hyperhomocysteinemia (HHcy)
Plasma levels greater than 15 µM are termed hyperhomocysteinemia (HHcy).
Based on plasma Hcy levels, HHcy can be categorized as mild (16-30 µM), moderate
(31-100 µM) and severe (>100 µM) [33]. Literature, however, suggests that plasma Hcy
levels above 10 µM, increases the risk for incidence of cardiovascular diseases [35]. A
clinical study done in 2004 reported an increase in the plasma Hcy levels of patients with
abdominal aortic aneurysm (15.7 ± 6.5 µM) [28] (Figure 3) and aortic dissection (Figure
3) [5, 36]. In patients with AAA, there was an increased trend in the expression of
SAHH, MTHFR and the expression of CBS when compared to healthy subjects [37]. A
similar trend was observed in patients with TAA. These results suggest a compensatory
increase in the Hcy metabolism proteins, MTHFR and CBS to combat HHcy during
aortic aneurysm (Figure 4) [37].
Genetic mutations and polymorphisms
Although several causative factors are responsible for HHcy, genetic mutation is
one of the most important influences (Figure 5). Mutations in the genes involved in the
Hcy metabolism pathway, inhibits their expression, resulting in changes in Hcy levels in
the body. Since folate is a cofactor in remethylation of Hcy, without MTHFR, plasma
Hcy levels increase. MTHFR polymorphisms impair the ability to process folate,
resulting in a defective Hcy remethylation pathway. The most common MTHFR
polymorphism is C677T (thermolabile mutation). In this mutation, the C->T conversion
10

in the gene code at nt 677 results in an alanine to valine substitution. This change in the
amino acid sequence decreases the activity of MTHFR at higher temperature
(thermolability). Wong et al., report that in AAA, plasma Hcy levels were greater in
MTHFR TT homozygote individuals than in wild type CC controls [38]. Another
MTHFR polymorphism is A1298C, where the A->C conversion in the genetic code at nt
1298 leads to aglutamate to alanine substitution. This polymorphism also results in
decreased MTHFR activity; however, its impact on tHcy is lesser than that of the C677T
mutation. Individuals heterozygous for both of these mutations exhibit decreased
MTHFR activity and plasma folate levels and increased tHcy [39]. In 1966, Mudd et al.,
report that people with HHcy due to a severe genetic defect of CBS, are affected with
premature arteriosclerosis and frequent thromboembolisms [40]. Since mutations in the
Hcy metabolism genes lead to accumulation of Hcy, knockout mice models for MTHFR
and CBS are predominantly used to study the pathogenic mechanisms of HHcy [9, 41].
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Figure 2: Overview of the homocysteine formation and metabolism pathway
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Figure 3: Total plasma Hcy (tHcy) levels are increased in patients with abdominal
aortic aneurysm (AAA) and aortic dissection. The above data are reproduced from a
2004 article by Dr. Giusti et al., [5]. The above data show an increase in tHcy levels in
aortic aneurysm and aortic dissection. (B – Patients with mild cardiovascular system
involvement C – Patients with major criteria in cardiovascular system)

13

Figure 4: CBS expression was increased in aortic aneurysm [37]. RNA extracted from
various human aortic tissue samples were reverse transcribed and amplified using primers
designed for CBS, MTHFR, SAHH. Data are shown as mean ± SEM. * p<0.05 vs.
normal controls, † p<0.05 vs. AAA (n=4). Ctrl – controls, AAA – abdominal aortic
aneurysm, TAA – thoracic aortic aneurysm, CBS – Cystathionine beta synthase, MTHFR
– Methylene tetrahydrofolate reductase, SAHH – S-adenosyl homocysteine hydrolase, bp
– base pairs
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Hyperhomocysteinemia and vascular dysfunction
In 1969, Kilmer McCully report subjects with homocystinuria, an inherited
disorder of HHcy and increased Hcy concentration in urine associated with CBS
deficiency, exhibit vascular complications including increased smooth muscle
proliferation, progressive stenosis and hemostatic changes [42, 43]. Several mechanisms
are proposed by which HHcy may lead to vascular damage. Hcy can induce oxidative
stress due to increased production of reactive oxygen species (ROS) [44, 45]. ROS
decreases the bioavailability of nitric oxide, a primary mediator of vasorelaxation,
reacting with nitric oxide and forming peroxynitrate. Hcy impairs endothelium-dependent
vasodilation due to reduced bioavailability of nitric oxide [44, 46], increased levels of
asymmetric dimethylarginine (an intermediate formed during proteolysis of methylated
proteins) [47] and endothelial dysfunction [48]. Hcy triggers the expression and release
of cytokines such as monocyte chemotactic protein 1 (MCP1) and IL-8, specific for
neutrophils and monocytes which cause inflammation [49-52]. Hcy can also induce
mobilization of intracellular calcium, causing platelet aggregation in type 2 diabetes
mellitus [53]. Other mechanisms suggest that Hcy enhances LDL oxidation and lipid
peroxidation [54-56], increases smooth muscle proliferation [57], causes abnormal
platelet function [58-60] and causes extracellular matrix remodeling in arteries [61] and
veins [62].
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Extracellular matrix remodeling
The structural design of different components of the extracellular matrix (ECM) is
necessary for understanding the mechanical properties of tissues. ECM is the non-cellular
component which provides physical scaffolding for the cellular constituents and initiates
crucial biochemical and biomechanical signaling mechanisms. ECM consists of different
types of components – Fibrous proteins like collagen and elastin; matrix
metalloproteinases and tissue inhibitor of matrix metalloproteinases.
Fibrous proteins - Collagen and Elastin
The fibrous proteins provide the structural support for vessels. Both collagen and
elastin make up the wall of the aorta. Collagen provides rigidity and is responsible for
the mechanical strength of the vessels. There are about 16 different types of collagen
known in the body. Col I is about 90% of all human collagen and is present in most
tissues. Col I, III, IV and V are abundantly found in arterial wall. Both Col I and III are
the major constituents of the intima, media and adventitia. There was a decrease in the
expression of Col I in AAA (Figure 6) [37]. Col IV and V are localized to the endothelial
basement membrane and basement membranes of smooth muscle cells of the intima and
media. In TAA, decreased expression of Col I and IV have been reported (Figure 6) [37] .
Diffusely distributed type V collagen was also observed in the intercellular space of the
intima [63].
Elastin is responsible for the reversible extensibility during cyclic loading of the
cardiac volume. Elastic fibers are organized in the medial layer of the aorta as an
interconnecting, fenestrated network. Each layer of elastic fibers is associated with
17

circumferentially oriented smooth muscle cells and collagen fibers and constitutes a
lamellar unit. The number of units is established during development and is directly
related to the tension in the arterial wall, so that the tension/lamellar unit is constant
across the body and the arterial tree [64]. Elastin undergoes degradation and alterations
with increasing age and various pathologies resulting in arterial wall stiffness [65].
Increased arterial stiffness is an important, independent predictor of cardiovascular
mortality in hypertension, end-stage renal failure, diabetes, and elderly adults [66].
Arterial stiffness triggers a negative feedback cycle that increases the mechanical load on
the heart and leads to heart failure [67].
Patients with homozygous CBS deficiency showed an increased internal and
external diameter of the common carotid arteries [68]. Arterial histological analysis of
homocystinuric patients showed medial changes and internal elastic laminal
fragmentations [69, 70].
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Figure 6: Collagen I was decreased in AAA and TAA tissues. RNA extracted from
various human aortic tissue samples were reverse transcribed and amplified using primers
designed for Collagen I, Collagen IV, Elastin. Data are shown as mean ± SEM. *p<0.05
vs. healthy controls (n=4), ‡ p<0.05 vs. healthy controls and TAA samples (n=4); AAA –
abdominal aortic aneurysm, TAA – thoracic aortic aneurysm, Ctrl – controls, Col1 –
Type 1 collagen, Col4 – Type 4 collagen
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Matrix metalloproteinases (MMPs)
Regulated ECM synthesis and degradation is necessary for development,
morphogenesis,

wound

healing,

and

tissue

repair

and

remodeling.

Matrix

metalloproteinases (MMPs), also known as matrixins, are responsible for the timely
degradation of ECM under normal physiological conditions. MMPs play a major role in
tadpole tail metamorphosis by Gross and Lapiere in 1962 [71]. MMPs are zinc and
calcium dependent endopeptidases which are primarily secreted in cells such as
fibroblasts, vascular smooth muscle, macrophages, neutrophils and mast cells. Based on
the molecular structure, substrate specificity and mechanism of activation, MMPs are
classified into four groups: archetypal MMPs, matrilysins, gelatinases and furin-activated
MMPs [72].
Archetypal MMPs are further divided into three subgroups: collagenases,
stromelysins and other archetypal MMPs. Collagenases are classified as: collagenase-1
(MMP-1), collagenase-2 (MMP-8), and collagenase-3 (MMP-13). Collagenases cleave
native collagens into characteristic N-terminal ¾ and C-terminal ¼ fragments. MMP-1
initiates cleavage of fibrillar collagens at a single site so that other MMPs can further
degrade collagen [73]. The main sources of collagenases are activated fibroblasts (MMP1), neutrophils (MMP-8) and vascular smooth muscle cells (MMP-1 and MMP-13).
Collagenases are abundantly present in aortic aneurysm tissues [74]. Stromelysins are
classified as stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10). Stromelysins are
structurally similar to collagenases, but they do not possess the ability to cleave native
collagens. MMP-3 is more proteolytic than MMP-10 and activates various pro-MMPs
[75, 76]. Although stromelysin is primarily produced by vascular smooth muscle cells
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and fibrobalsts, in aortic aneurysm they are derived from macrophages. Other archetypal
MMPs include MMP-12, MMP-19, MMP-20 and MMP-27. MMP-12, macrophage
metalloelastase, is primarily expressed and secreted by activated macrophages and
mainly cleaves elastin.
Matrilysins lack a hemopexin domain and are represented by matrilysin-1 (MMP7) and matrilysin-2 (MMP-26, or endometase). Matrilysins play an important role in
degradation of ECM molecules, including Col IV, laminin and may be responsible for
apoptosis and inhibition of angiogenesis. MMP-26 is the smallest known MMP and is
involved in the activation of MMP-9 [77].
Gelatinases consists of gelatinase A (MMP-2) and gelatinase B (MMP-9). Both
are constitutively expressed by cells, including fibroblasts, keratinocytes, endothelial
cells, polymorphonuclear leukocytes, monocytes, alveolar macrophages and osteoclasts.
When compared to other MMPs, gelatinases possess three type II fibronectin-like repeats
within their catalytic domain. Gelatinases may cleave various ECM substrates such as
gelatin, collagen types I, IV, V, VII, IX, X, elastin, fibronectin, aggrecan, vitronectin,
laminin, as well as non-ECM molecules, including pro-TNF, TGF-β, pro-IL-1β and proIL-8 [78]. MMP-9 is the most abundant elastase in human AAA tissue.

It is also

expressed by aneurysm-infiltrating macrophages at the site of damaged tissue. MMP-9 is
correlated with higher aneurysm diameters (Figure 7) and is present in high amounts in
the plasma of patients with AAAs [79].
Furin-activated MMPs have a unique sequence inserted between the prodomain
and the catalytic domain which is cleaved by furins (pro-protein convertases or serine
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proteinases), thereby activating the enzymes. These MMPs are divided into two
subgroups: secreted MMPs, (membrane-type I and type II MMPs) and GPI-anchored
MMPs. The furin-activated secreted MMPs include MMP-11, MMP-21 and MMP-28.
Type I transmembrane MMPs include: MT1-, MT2-, MT3-, and MT5-MMP (MMP-14, 15, -16, and -24, respectively. Type II transmembrane MMPs consist of MMP-23A and
MMP-23B and GPI-anchored MMPs include MT4-MMP and MT6-MMP (MMP-17 and
-25, respectively). MT-MMP-1 plays an important role in the pathogenesis of aortic
aneurysm. Besides degradation of ECM components, MT1-MMP activates MMP-2 and
facilitates migration of macrophages, thus promoting inflammatory infiltration of the
aortic wall [74].
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Tissue inhibitors of MMPs
Tissue inhibitors of matrix metalloproteinases (TIMPs) prevent aortic wall
destruction and prevent aneurysm development by inhibiting MMPs [80]. TIMPs are
secreted by cells, including macrophages, VSMC and platelets. TIMPs bind to the
catalytic domain of MMPs and block their enzymatic activity. TIMPs possess differential
affinity to MMPs, for example, TIMP-1 preferably binds to MT-MMPs. The presence of
MMP-neutralizing agents such as α2-macroglobulin prohibits a direct interaction between
TIMPs and active MMPs [81]. TIMP-1 is a collagenase inhibitor while TIMP-4 is
secreted extracellularly primarily from heart tissue and may be involved with
extracellular matrix homeostasis [82]. TIMP-2 plays a major role in the activation of
MMP2. TIMP-2 binds to the hemopexin domain of pro-MMP-2 which is necessary for
MT1-MMP to activate MMP-2 [83].
Functional polymorphisms in genes encoding for TIMPs could influence the
activity of MMPs in the aneurysm wall. Several single nucleotide polymorphisms (SNPs)
which could affect TIMP transcription were assessed in patients with aortic aneurysms.
The genotyping results were analyzed for male and female patients separately since the
TIMP-1 gene is located on the X chromosome. The literature suggests that two
polymorphisms for TIMP-1 (434 C/T and rs2070584 T/C) [84] and two for TIMP-2 (a
promoter SNP -479 C/T, and 573 G/A, but in male patients group only) [85, 86] are
associated with aortic aneurysm. Although TIMP-1 mRNA expression levels did not
change significantly, TIMP-4 mRNA levels were higher in abdominal aortic aneurysm
when compared to normal healthy controls (Figure 7).
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Figure 7: TIMP4 expression was increased in AAA [37]. RNA extracted from various
human aortic tissue samples were reverse transcribed and amplified using primers
designed for MMP1, TIMP1, MMP9, TIMP4. Data are shown as mean ± SEM. *p<0.05
vs. normal (n=4) ; AAA – abdominal aortic aneurysm, TAA – thoracic aortic aneurysm,
Ctrl – control, MMP – matrix metalloproteinase, TIMP – tissue inhibitor of
metalloproteinase

24

Epigenetic Modifications
In a eukaryotic nucleus, the basic unit of chromatin consists of 147 base pairs of
DNA wrapped around two copies of four histone proteins H2A, H2B, H3 and H4 [87].
Histone proteins consist of a globular carbosyl-terminal domain and an amino-terminal
tail which project from the nucleosome core. The amino tails of the histone proteins are
susceptible to post translational modifications such as acetylation, methylation,
phosphorylation, ubiquitination, sumolysation and ADP-ribosylation [88]. These
inheritable histone modifications affect gene transcription, and maintenance of epigenetic
information by making a histone modification signature or a “histone code” [89].
Epigenetics can be described as the inheritable changes occurring beyond the
genetic makeup, without affecting the actual nucleotide sequence. Every organism carries
a certain epigenetic pattern throughout its pedigree. These epigenetic patterns are
translated to phenotypic expression due to the regulation of gene transcription exerted by
the epigenetic modifications.

However, this epigenetic blueprint can be altered by

various environmental factors like diet, hormonal imbalance during physical stress and
pollutants [90-92]. The most commonly studied epigenetic modifications are – DNA
methylation and histone modifications (Figure 8). Normally, histone modifications have
short-term gene expression effects and DNA methylation is considered to be long-term
silencing of gene expression where both of the mechanisms are interdependent.
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DNA Methylation
DNA methylation is an epigenetic modification involving an addition of methyl
group to the cytosine residues at the 5-carbon position. Methylated cytosine (5-mC), was
first described in 1925 by Johnson and Coghill [93]. In mammals, 5-mC is primarily
found in cytosine-guanidine rich regions in the gene called CpG islands. They account for
approximately 7% of CpG dinucleotides genome-wide and are associated with the 5′regulatory regions of ≈40% to 60% of human genes [94, 95]. These islands are found
mostly at the upstream promoter regions of the genes. Since promoter region
modifications are essential in regulating the binding of transcription factors, CpG island
methylation plays a major role in controlling gene expression. In healthy somatic cells,
70% to 90% of CpG dinucleotides, representing 3% to 6% of all cytosines, are
methylated [95]. DNA methylation is facilitated with the help of DNA methyltransferases
(DNMTs). There are mainly three active DNMTs : DNMT1, DNMT3a and DNMT3b.
DNMT3a and 3b facilitate de novo methylation which is responsible for methylation
patterns during early embryo development [96]. DNMT1 is primarily found in somatic
cells and is localized to the DNA replication fork, where it is specific to hemi-methylated
DNA. It is involved in maintenance methylation.
DNA methylation is associated with transcriptional silencing in a growing number
of cellular functions, such as X chromosome inactivation, genomic imprinting,
mammalian embryonic development, and lineage specification [94, 95]. Aberrant DNA
methylation patterns have been associated with various diseases. For example, the cancer
genome

is

characterized

by

genome-wide

hypomethylation

and

hypermethylation of CpG islands associated with tumor-suppressor genes.
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paradoxical

DNA methylation can affect gene expression in two different ways. First, since
methyl groups of CpG dinucleotides project into the major groove of the DNA helix, it
prevents the binding of transcription factors such as Myc, activator protein-2, -19,
hypoxia-inducible factor -1α, -20 and the insulator protein CTCF21, -22 to CpG
dinucleotide-containing cis-DNA binding elements. However it is likely that this
mechanism is not relevant for a majority of transcription factors whose target genes are
regulated by DNA methylation [95]. Second, a group of methyl-CpG binding proteins are
capable of specifically recognizing the mammalian methylated CpG rich regions which
act as transcriptional repressors.

These include proteins containing a homologous

methyl-CpG-binding domain (MBD1, MBD2, MBD4, and MeCP2) and nonhomologous
protein, Kaiso, which is capable of binding methylated CpG dinucleotide doublet [97].
These proteins can directly repress transcription, prevent the binding of activating
transfactors, or alter the structure of chromatin and promote transcriptional repression.
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Histone Modifications
Although the nucleosome is a tight structure, histone post-translational modifications can
affect the chromatin structure and function and hence modulate the accessibility of
transcriptional regulators to cis-DNA binding elements. Histone modifications at a
certain promoter region determine the epigenetic state of the genome, and one of the most
important types of histone modifications is acetylation [98]. Histone acetylation
neutralizes the positive charge of the lysine residues, thereby disrupting the electrostatic
attraction between histone proteins and negatively charged DNA. This interaction results
in a change from heterochromatin to euchromatin, allowing the transcription initiation
complex to access DNA promoter. Thus, euchromatin is the transcriptionally active
region and is associated with acetylated histones and hypo-methylated DNA.
Heterochromatin, however, is transcriptionally repressed and bound to non-acetylated
histones and hyper-methylated.
Histone acetylation is regulated by the balanced activities of two key enzymes - histone
acetyl transferase (HATs) and histone de-acetylase (HDACs) [99]. HATs acetylate lysine
residues and result in an open chromatin promoting gene transcription, whereas HDACs
remove acetyl groups and condense the chromatin causing transcriptional repression
[100]. Some proteins function as transcriptional activators such as p300 which possess
intrinsic HAT activity [99]. A previous report suggests that HAT and HDACs play a
major role in the development of atherosclerosis and restenosis due to their regulatory
role in processes such as inflammation, proliferation of VSMCs and matrix remodeling
[101]. HDACs aid in maintaining endothelial function and structural integrity of the
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vessels by regulating the expression of proteins involved in angiogenesis such as vascular
endothelial growth factor [102, 103]
Histones methylation takes place on either lysine (K) or arginine (R) residues providing
binding sites for recruitment of other regulatory proteins [104]. Methylated histones such
as H3K9, H3K27, H3K79 and H4K20 are associated with gene repression, whereas
activated genes are associated with methylated H3K4 and H3K36 residues [104]. Histone
methylation is carried out by histone methyl transferase (HMT), whereas histone
demethylases (HDMs) remove methylation. Proteins involved in DNA methylation
mechanism such as DNA methyl transferase and methyl-binding proteins interact with
histone-methylating enzymes, resulting in cross talk between the histone and DNA
methylation pathways [104]
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Figure 8: Illustration showing epigenetic modifications which play a major role in
regulating gene transcription. DNMT – DNA methyltransferase, MBD – Methyl
binding domain, HAT – Histone acetyltransferase, H3K9 – Histone 3 at lysine 9, HDAC
– Histone deacetylase
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CHAPTER III
HYPOTHESIS AND SPECIFIC AIMS

Key Objective
To investigate effects of epigenetic modifications, such as DNA methylation, on
aortic remodeling and hypertension during HHcy.
Hypothesis
Upregulation of global DNA methylation in hyperhomocysteinemia dysregulates cellular
mechanisms causing endothelial dysfunction and adverse extracellular matrix remodeling
leading to hypertension
Specific Aims
•

Specific Aim 1: To determine whether HHcy increases the activity of
methyltransferases and histone methylation to alter ECM metabolism in aorta.
The experimental results associated with Aim 1 are presented in chapter IV.
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•

Specific Aim 2: To determine whether DNA methylation inhibitor, 5 Aza 2’
deoxycytidine (Aza) alleviates HHcy, improves smooth muscle and endothelial
function and normalizes blood pressure.

•

Specific Aim 3: To determine whether Aza mediates its effects by modulating the
expression of proteins involved in ECM regulation.
The experimental results associated with Aim 2 and 3 are presented in chapter V.
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Figure 9: Schematic diagram of overall hypothesis. Epigenetic modifications regulate
aortic remodeling resulting in hypertension during HHcy.
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CHAPTER IV
AORTIC REMODELING IN HYPERHOMOCYSTEINEMIA
Introduction
Hcy is a risk factor for diseases such as stroke, ischemic heart disease, peripheral vascular
and aortic diseases [105]. Although the normal range of homocysteine in the blood is
around 5–15 µmol/L, the range varies with age and sex as well as nutritional factors
[106]. HHcy is found in a study of 86 hypertensive patients compared to 82 normal
healthy controls [107]. Plasma Hcy levels are positively correlated with blood pressure in
human subjects with methionine loading [108]. Arteriosclerosis is prevalent in patients
with increased homocysteine due to genetic defects in enzymes involved in Hcy
metabolism, such as cystathionine beta-synthase (CBS) and methylene tetrahydrofolate
(MTHFR) and in patients with nutritional deficiency of folic acid, vitamin B6 and B12.
Hcy promotes arterial stiffness by increasing the synthesis of ECM components such as
collagen. Collagen provides rigidity and structure to the arterial wall, while elastin
provides distensibility by allowing blood vessels to resume their shape after stretch or
contraction. During HHcy, the imbalance between elastin and collagen production
destroys proper elasticity of the vessel and excessive collagen deposition causes vascular
stiffness and tissue fibrosis. These effects increase vascular resistance for blood flow that
results in arterial hypertension.
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DNA methylation is an important epigenetic mechanism in transcriptional regulation of
many genes. The methyl group is usually attached to the cytosine residue in the
nucleotide sequence with the help of specific enzymes called DNA methyl transferases
(DNMT) [109] There are two types of methylation involved – de novo methylation by
DNMT 3a and DNMT 3b and maintenance methylation, by DNMT1. Methyl binding
domain (MBDs) proteins like MBD2 have been shown to bind to these methylated CpG
islands and down-regulate transcription of downstream sequences by recruiting corepressor complexes [110]. These co-repressor complexes are proteins which are bound
to chromatin remodeling proteins like Histone 3 which is trimethylated at lysine 9
(H3K9) [111], and HDACs. Hcy induced DNA methylation plays an important role in
atherosclerosis [112]. In the current study, aortic tissue samples from wild type mice
(C57BL/6J) and CBS +/- mice ( with high methionine diet) were taken and mRNA
expression levels of various genes involved in methylation such as DNMTs, MBD2 and
H3K9 and genes involved in ECM metabolism such as collagen and elastin were
measured to study the correlation of DNA methylation and ECM metabolism in HHcy. It
was hypothesized that high levels of Hcy due to defects in methionine metabolism cause
increased global methylation which induces remodeling of the aortic wall.
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Methods:
Mouse tissue samples
CBS +/- (B6129P2) mice and their wild type littermates (WT, C57BL/6J) were obtained
from The Jackson Laboratories. CBS +/- mice were fed with a high methionine diet for
three weeks in order to create the HHcy condition. Aortic tissue was isolated from WT
and CBS+/- mice.
Blood Pressure Measurements
Blood Pressure was measured by a noninvasive tail-cuff method (CODA; Kent Scientific,
Torrington, CT). Animals were placed on a warming platform at 37C and allowed to
acclimatize for 10 min before measurements were taken. Systolic, Diastolic and Mean
arterial blood pressure were recorded in WT and CBS+/- mice.
Plasma Hcy Measurement
Plasma Hcy levels were measured using HPLC-UV as described before.[113-115]
Reverse transcription polymerase chain reaction (PCR)
Total RNA was isolated from mouse aortic tissue using Trizol reagent (Invitrogen) [116].
One microgram (1 µg) of total RNA was reverse transcribed using the Reverse
Transcription System (Promega), according to the manufacturer’s instruction. Primers, to
amplify specific gene sequences, were designed using Primer3 [117] and obtained from
Invitrogen (Carlsbad, CA). The list of primers is given in Table 2. PCR was done in a
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Biorad DNAEngine Thermal cycler (Hercules, CA). The PCR thermal cycle was 95C
for 7 mins, 35 cycles of 95C for 50 s, 55C for 1min and 72C for 1min, and 72C for 5
mins. PCR products were resolved by gel electrophoresis in 1% or 1.5 % agarose gels
and the

images were recorded and analyzed using Imagelab software (Bio-Rad,

Hercules, CA). The band intensities of the PCR product were normalized to GAPDH.
Immunostaining
Mouse aortic tissue was collected and cryo-blocks were prepared in Peel-A-Way
disposable plastic tissue embedding molds (Polysciences Inc., Warrington, PA., USA)
containing tissue freezing media (Triangle Biomedical Sciences, Durham, N.C., USA)
and stored at -80°C until further use. Five micron (5 μm) tissue sections were made using
a Cryocut (Leica CM 1850) and placed on Super frost plus microscope slides, air-dried
and processed for immunohistochemistry (IHC). Slides were fixed using 3.7%
paraformaldehyde, permeabilized and blocked with blocking solution (2% BSA and 0.5%
Triton X-100 in PBS). Slides were incubated with mouse polyclonal anti-Histone 3 trimethyl K9 (Abcam, Cambridge, MA) overnight. Alexa Fluor 488 raised in mouse from
Invitrogen (Carlsbad, CA) was used as the secondary antibody. The stained slides were
mounted and visualized with a laser scanning confocal microscope (Olympus
FluoView1000) with appropriate filters. Images were analyzed using Image Proplus
software taking different optical fields at random into consideration.
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Quantification of 5-methylcytosine
Genomic DNA was extracted (Zymo Research Corp., Irvine, CA, USA) from the aortas
of mice from the experimental groups. In order to measure levels of global methylation,
the amount of 5-methylcytosine (5-mC) was determined using ELISA (Zymo Research
Corp., Irvine, CA, USA), as per the manufacturer’s instructions. Samples were read at
410 nm and the values are represented as percent of 5-mC
Statistical Analysis
Statistical analysis was done using Primer of Biostatistics to compare data collected from
groups. Differences between CBS+/- and controls were determined by t-test. A
probability level (p<0.05) is considered statistically significant. All values are presented
as mean ± SEM.
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Results:
Plasma Hcy and blood pressure measurements in CBS+/- mice
Plasma Hcy levels in CBS+/- mice increased when compared to WT mice (Figure 10).
Systolic, diastolic and mean blood pressure in CBS+/- mice was also increased when
compared to WT mice (Figure 11).
Expression of metabolites involved in remodeling proteins in mice aortic tissue
samples
To evaluate the expression of ECM fibrillar proteins, mRNA levels of collagen and
elastin were assessed in WT and CBS+/- mice fed with a methionine diet (Figure 12). On
an average, the expression of Col1a1 in CBS+/- mouse aorta was increased when
compared to WT but the increase did not reach statistical significance. The mRNA levels
of Col4a1 were significantly increased in CBS +/- mouse samples when compared to WT
controls. In contrast, the level of Elastin was found to be decreased significantly in CBS
+/- samples compared to WT (Figure 12).
Expression levels of genes involved in epigenetic modifications in mouse aortic
samples
DNA methylation levels were analyzed by measuring %5-mC and mRNA levels of the
enzymes, DNMT1, 3a and 3b that are involved in DNA methylation. CBS+/- mice had a
higher %5-mC aortic content when compared to WT mice aorta suggesting global
methylation in HHcy (Figure 13). There was an increasing trend of DNMT 1 and 3a
levels in CBS +/- mice with high methionine diet when compared to WT mice (Figure
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14). However, there was no change in DNMT3b levels in aortic samples from WT and
CBS +/- mice. To study levels of methyl binding proteins and histone methylation,
mRNA expression levels of MBD2 and H3K9 (trimethyl) respectively, were measured in
CBS+/- mice. MBD2 and Histone 3 trimethylation in lysine 9 (H3K9) expression levels
were increased in CBS +/- mice compared to WT (Figure 15, 16). However, there was no
significant difference in the histone deacetylase 1 (HDAC1) mRNA levels between WT
and CBS+/- mice (Figure 15).
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Figure 10: Plasma Hcy was increased in aortic tissue from CBS+/- mice. Plasma Hcy
levels in WT and CBS+/- mice were measured using HPLC-UV. Data are shown as mean
± SEM. n=4; * p<0.05 vs. WT
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Figure 11: Blood pressure was increased in HHcy mice. Blood pressure in WT and
CBS+/- mice was measured by the tail-cuff method. Systolic, Diastolic and Mean blood
pressure data are shown as mean ± SEM. n=4; * p<0.05 vs. WT
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Gene
Collagen - I

Primer pair sequence (5’-3’)

Product
size (bp)

AGAACTTTGCTTCCCAGATG

162

CTATCTGTACCACCCCCTTG
Collagen - IV

GCTGCTAAGAACTTGCCTTC

105

GGGGACAGAGAAGATGTCAC
Elastin

TGACAGTATAGGGCTGAGCA

238

GAGTTGTTGTGGGTGAGACA
DNMT1

GGGTCTCACCAAGTATCTCA

235

GGTGTGTGACTCCAGTTTTT
DNMT3a

GGGAGAGAGGGAAAATTCTA

298

GGTTTTCTTCAAGGTTTCCT
DNMT3b

GACTGCCTGGAGTTCAGTAG

285

ACAGGCAAAGTAGTCCTTCA
GAPDH

TAAATTTAGCCGTGTGACCT

177

AGGGGAAAGACTGAGAAAAC
MBD2

TAGCGCATCAGATGTAACAG

199

AGAGACTTGTCCTGTGATGG
H3K9

CTGTCTCAAAGAAGGAGGTG

279

GGACAGACAAACACCAAAGT
HDAC1

GACTGGACCCTCTGTCATTA
TTTCTCCTAAAGTGCAGCTC

Table 2: List of primers used in murine aortic samples.
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Figure 12: Collagen 4 was increased and elastin was decreased in HHcy.
Representative RT-PCR image of collagen 1a1 (Col1A1), 4a1 and elastin mRNA
expression. GAPDH was used as a loading control. The mRNA expressions were
determined by densitometry analysis using Biorad Imagelab software. The intensity
values were normalized by GAPDH intensity. n =3. Data are shown as mean ± SEM. *,#
p<0.05 vs. WT.
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Figure 13: Global hypermethylation in HHcy aorta. Bar graph representing percent 5mC detected in WT and CBS+/- mice aorta genomic DNA samples. Data are shown as
mean ± SEM for n=4. *p<0.05 vs. WT.
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DNMT 3a
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Figure 14: Increasing trend of DNMTs in aorta of HHcy mice. Representative RTPCR image of DNMT1, 3a and 3b mRNA expression. GAPDH was used as a loading
control. Graphical representation of mRNA expressions as determined by densitometry
analysis using Biorad Imagelab software. Intensity values were normalized by GAPDH
intensity. n =3. Data are shown as mean ± SEM.
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Figure 15: Increasing trend in expression of methylation genes in aorta of HHcy
mice. Representative RT-PCR image of MBD2, H3K9 and HDAC1 mRNA expression.
GAPDH was used as a loading control. Graphical representation of mRNA expressions
as determined by densitometry analysis using Biorad Imagelab software. The intensity
values were normalized by GAPDH intensity. n =3. Data are shown as mean ± SEM
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Figure 16: H3K9me3 expression was increased in HHcy mice aorta. Immunostaining
of aorta sections with H3K9 (trimethyl) antibody (green fluorescence). Bar diagram
indicate the intensity values as determined by Image Pro software. n =3. Data are shown
as mean±SEM. Original image x60 magnification. *p<0.05 vs. WT
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Discussion:
Previous studies report that Hcy is a leading risk factors which is responsible for
aortic disease progression such as aortic dissection [5, 118, 119]. Elevated levels of Hcy
in plasma, known as HHcy, trigger various effects such as impaired post-injury
endothelial repair and function, deregulation of lipid metabolism, altered platelet activity,
enhanced VSMC proliferation, activation of cellular immune response, all of which are
believed to be primary characteristics in the development of vascular pathologies such as
atherosclerosis and abdominal aortic aneurysm (AAA) [120-125]. Recent studies
emphasize the role of epigenetic modifications such as DNA methylation in the
regulation of the transcription of enzymes involved in various mechanisms including
platelet activity and VSMC proliferation [126, 127]. The present study demonstrated the
effect of HHcy on global DNA methylations in the aorta. Increased levels of plasma Hcy
correlated with increased blood pressure in CBS+/- mice when compared to WT.
Concurrent to our findings, Lim and Cassano et al., previously reported that a 5 μmol/L
increase in plasma Hcy causes an increase of systolic and diastolic blood pressure by
0.7/0.5 mmHg in men and 1.2/0.7 mmHg in women [108]

Hcy increases the synthesis and accumulation of collagen in a dose dependent
manner in VSMCs [124]. Atherosclerosis is characterized by increased smooth muscle
proliferation and accumulation of ECM components, resulting in arterial intimal
thickness [128-130]. Collagen provides rigidity to the artery wall and accounts for about
60% of the ECM components responsible for the formation of atherosclerotic plaques
[131]. Our results showed an increase in Collagen 1 and 4 levels in aortic tissue samples
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from HHcy CBS +/- mice. In addition, a significant decrease in elastin levels in aortic
tissue from CBS +/- mice was observed when compared to WT. An increased collagen to
elastin ratio due to increased collagen and decreased elastin levels in CBS +/- mice
accounts to carotid arterial remodeling [132]. Elastin provides distensibility to the vessel
wall and a decrease in elastin content increases the vascular resistance to blood flow
resulting in hypertension. These findings suggest that adverse aortic ECM remodeling
associated with HHcy, may cause hypertension.
HHcy alters the methylation patterns in the genome globally and in a gene
specific manner. DNA methylation plays a predominant role in regulating gene
expression. CBS knockout mice have a tissue specific fluctuation in their DNA
methylation levels [133]. S- adenosyl methionine (SAM), an intermediate in the Hcy
synthesis pathway, serves as the universal methyl donor for the methylation of various
substrates such as DNA and proteins. Our results showed an increase in %5-mC and
mRNA levels of DNMT1, and 3a in aortic tissue from HHcy mice. This finding
suggested that an increase in synthesis of Hcy causes DNA hypermethylation. DNA
methylation arrays in peripheral leukocytes of subjects with schizophrenia indicate a
positive correlation between plasma Hcy and methylation of CpG residues in CpG islands
[134]. Other epigenetic mechanisms such as histone methylation and methyl binding
proteins act in conjunction to regulate genome wide transcriptional activity. The mRNA
expression of MBD2 and Histone 3 trimethylated in Lysine 9 residue (H3K9) proteins
suggested an increase in the expression of histone methylation and methyl binding
proteins in HHcy. In addition, we studied mRNA expression of HDAC 1 but no
significant change was found in the samples.
50

In summary, results of our study, combined with previous findings concerning the
effect of Hcy on adverse ECM remodeling, delineate possible epigenetic mechanisms
involved in aortic pathologies. Although evidence suggests an association between gene
promoter specific hyper-methylation and atherosclerosis [29], extensive studies of the
role of methylation in regulating various genes up or down in other aortic pathologies
such as aortic aneurysm still need to be done.
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CHAPTER V
EFFECT OF 5-AZA-2’DEOXYCYTIDINE IN AORTIC REMODELING IN
HYPERHOMOCYSTEINEMIA
Introduction
Aortic disease is one of the most prevalent causes of increased mortality in the world
[135-137]. Several risk factors including hyperglycemia, high serum cholesterol and
elevated level of homocysteine (Hcy), known as hyperhomocysteinemia (HHcy), are
associated with aortic aneurysm and atherosclerosis [138, 139]. The vascular pathology
associated with HHcy is characterized by excess extracellular matrix (ECM) turnover,
causing increased deposition of collagen, leading to vessel stiffness [140, 141]. Under
physiological conditions, ECM homeostasis is maintained by equilibrium between matrix
metalloproteinases (MMPs) and their inhibitors, tissue inhibitors of metalloproteinases
(TIMPs). Previous literature demonstrated that HHcy increases the expression and
activity of MMP-9 which causes matrix degradation and accumulation of collagen in the
ECM [142]. Arterial hypertension is associated with endothelial dysfunction [143]. HHcy
causes auto-oxidation of sulfhydryl groups, promoting reactive oxygen species
production which uncouples endothelial nitric oxide synthesis and reduces nitric oxide
(NO) synthesis and bioavailability [144-146]. A reduction in NO signaling further
increases superoxide generation, forming a vicious cycle and impairs endothelial
function. The functional consequence of endothelial dysfunction impairs vasodilation
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resulting in arterial hypertension [147, 148]. Hcy is a non-protein coding amino acid
synthesized by de-methylation of methionine. The methyl group which is excised during
the synthesis of Hcy is used in various methylation reactions involving DNA, proteins,
amino acids and Hcy [149]. DNA methylation is one of the most intensely studied
epigenetic mechanisms in the development of aortic diseases. There are three DNA
methyl transferases (DNMTs) involved in DNA methylation: DNMT1 which is involved
in maintenance methylation and DNMT3a and 3b which catalyze de novo methylation
[150]. Current research is focusing on the use of DNMT inhibitors in several disease
conditions. Decitabine or 5-Aza-2’-deoxycytidine (Aza), a DNMT1 inhibitor is approved
by the FDA for treatment of myelodysplastic syndrome (MDS). Other inhibitors such as
Vidaza (5 Aza cytidine) are currently in phase 2 and phase 3 cancer trials [151].
The purpose of the present study was to investigate the role of DNA methylation in aortic
ECM remodeling and vascular dysfunction in HHcy associated hypertension. We
hypothesized that increased levels of Hcy and DNMT1 result in adverse ECM
remodeling and endothelial dysfunction, leading to arterial hypertension. We also
examined whether DNMT1 inhibitor, Aza could modulate ECM metabolism enzymes to
mitigate hypertension. The results showed that Aza treatment in HHcy mice protects the
aorta by regulating epigenetic mechanism of genes involved in ECM metabolism.
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Materials and Methods
Antibodies and reagents
Monoclonal antibodies to DNMT1, DNMT3b, Methylenetetrahydrofolate reductase
(MTHFR) (mouse) and DNMT3a, MMP9, TIMP1, Hcy (rabbit) were purchased from
Abcam (Cambridge, MA), mouse polyclonal antibody S-adenosyl homocysteine
hydrolase (SAHH) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The
following secondary fluorescent antibodies were used: Texas Red anti-rabbit, Alexa
Fluor 488 anti-mouse from Invitrogen (Carlsbad, CA). The following horse radish
peroxidase (HRP) conjugated secondary antibodies were used : anti-mouse and antirabbit from Santa Cruz Biotechnology (Santa Cruz, CA).
Animal Models
Male C57BL/6J (wild type; WT) and Cystathionine beta-synthase heterozygous
knockout; CBS +/- (B6129P2) mice, aged 8–12 weeks, obtained from Jackson
Laboratories (Bar Harbor, ME) were used in this study. The disruption of the
Cystathionine beta-synthase (CBS) gene in this heterozygous model, results in mild
HHcy. All mice were fed standard chow (Lab diet 5010, St. Louis, MO) and water ad
libitum. WT and CBS+/- mice were treated with 5-Aza-2’-deoxycytidine (Aza; Sigma, St.
Louis, MO) for four weeks by intraperitoneal injection (100μL, 0.5mg/kg body weight;
three consecutive times every week). Control animals received saline injections only.
Animals were divided into four groups: WT, WT treated with Aza (WT+Aza), CBS+/-,
and CBS+/- treated with Aza (CBS+/- +Aza). At least four animals (n ≥ 4) were used in
each group. All procedures were done according to National Institutes of Health
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guidelines and approved by the Institutional Animal Care and Use Committee of the
University of Louisville, School of Medicine.
Cell Culture
Mouse aortic smooth muscle cells (SMCs) from ATCC (Manassas, VA) were cultured in
6-well TPP (Techno Plastic Products, Trasadingen, Switzerland) cell culture plates with
DMEM medium containing 10%FBS and 0.2 mg/ml G-418. Cells were allowed to grow
to about 60% confluence and treated with 80µM Hcy and 100µM Aza for 48 hours.
Blood Pressure Measurements
Blood pressure (BP) was measured in conscious mice by a non-invasive tail cuff method
(CODA, Kent Scientific, Torrington, CT). Animals were allowed to acclimatize in the
restraining chambers on a warm platform for short duration (20-30 min) for a few days
before data was recorded. Under standard conditions (room temperature, lighting, and
quiet surroundings) BP was recorded weekly before and after starting Aza treatment
including systolic, diastolic, and mean pressures.
Ultrasound
Under isoflurane anesthesia, aorta ultrasound was done using a Vevo 2100 system
(Visual Sonics, Toronto, ON, Canada) before and after Aza treatment. The thoracic and
abdominal area was depilated and the animal was placed supine on a warm platform
(37°C). Using a MS550D (22-55 mHz) transducer, the thoracic and abdominal aorta were
imaged. Cross-sectional images of the aorta in the B Mode were used to measure wall
thickness and lumen diameter to obtain wall-to-lumen ratio. Peak systolic velocities
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(PSV) and end-diastolic velocities (EDV) values were measured in pulsed-wave doppler
mode. Resistive index (RI) was calculated using the following equation: RI = (PSVEDV)/PSV.
Plasma Hcy metabolite levels
Plasma levels of SAM, SAH and Hcy were analyzed using HPLC-UV as described
before [113-115].
Vascular reactivity studies with aortic rings:
Aortic ring preparation – The thoracic aorta was extracted from euthanized mice and
immersed in Kreb’s solution (pH 7.4, 37 ° C) containing (in mM): 118 NaCl, 4.7 KCl,
2.5 CaCl2, 1.2 KH2PO4, 1.2 MgSO4, 12.5 NaHCO3, and 10.9 D-glucose. Aortic rings
were prepared by cutting 2 mm wide segments and attached to an isometric force
transducer with two tungsten wire triangles [0.002 in. diameter, (Scientific Instruments
Services, Ringoes, NJ)] in a tissue myobath (Radnoti, Monrovia, CA) which was
continuously aerated with 95% O2-5% CO2. Rings were stretched to develop 0.5 g
optimal resting tension and equilibrated for an hour to obtain baseline measurements
using a DigiMed Tissue Force Analyzer (Micromed, Louisville, KY) [152].
Response to Phenylephrine, Acetylcholine and Sodium Nitroprusside - After a baseline
recording, vasoconstriction was studied by adding different concentrations of
phenylephrine (Phe) from 10−6 to 10−2 M to the organ bath to make final concentrations
of 10−9 to 10−5 M, respectively. Once maximal constriction was reached at 10-5M Phe,
Acetylcholine (Ach) was added to the organ bath similar to Phe in gradually increasing
concentrations to detect endothelial-dependent vasorelaxation. The tissue rings were
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washed with fresh Kreb’s solution and pre-constricted with a maximum dose of Phe
followed by 10-5M Sodium nitroprusside (SNP) to study endothelium-independent
vasorelaxation. The tissue responses were recorded for 10 min for each drug
concentration using DMSI-410 1.8.27 software (Micromed, Louisville, KY).
Cryosectioning
Aortic tissue was cryopreserved in Peel-A-Way disposable plastic tissue-embedding
molds (Polysciences, Warrington, PA) containing tissue-freezing media (Triangle
Biomedical Sciences, Durham, NC). Tissues were stored at –80°C until use. Serial
sections of 7-μm thickness were made using a Cryocut (Leica CM 1850). Cryosections
were placed on Superfrost plus microscope slides, air dried and stored at –80°C until
further use.
Collagen staining
To measure the deposition of collagen in the aortic wall, sections were stained with a
Masson trichrome kit (Richard Allan Scientific, Kalamazoo, MI) following the
manufacturer’s instructions. Collagen deposition is shown as blue color. Images were
captured with a light microscope (Olympus FluoView1000; B&B Microscope Ltd,
Pittsburg, PA). Sections were stained separately to differentiate type I and III collagen
using Picrosirius red staining kit (Polysciences, Inc., Warrington, PA) [153]. Images were
captured under polarized light filter (Olympus FluoView1000; B&B Microscope Ltd,
Pittsburg, PA).
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Immunostaining
Immunofluorescence staining was done on 7-μm thick aortic sections using antiMTHFR, MMP9, TIMP1, SAHH, DNMT1 and Hcy antibodies. Images were captured
using a confocal microscope (Olympus FluoView1000; B&B Microscope Ltd, Pittsburg,
PA) and analyzed by Image Proplus 7.0 software (Media Cybernetics, Inc., Rockville,
MD).
Immunoblotting
Protein was extracted from cultured SMCs using RIPA lysis buffer (Boston BioProducts,
Worcester, MA) with protease inhibitors. Protein concentration was determined using the
Bradford assay and 50µg of total protein was loaded in SDS-PAGE gels. Protein was
resolved by electrophoresis, transferred to a PVDF membrane and incubated with
primary antibody and secondary HRP- conjugated antibody. Protein bands were detected
using ECL substrate (Millipore, Billerica, MA). Bands were detected using Imagelab
(Biorad, Hercules, CA) and normalized by a GAPDH control. The band intensities were
quantified using ImageJ software.
Gelatin Zymography
Cultured SMCs were scraped with extraction buffer [10 mmol/l cacodylic acid, 20 ZnCl,
1.5 NaN3 and 0.01% Triton X-100 (pH 5.0)] and incubated overnight at 4C with gentle
agitation. The homogenate was centrifuged for 5 min at 10000 xg and the supernatant
was collected. Protein concentration in the sample was measured using the Bradford
method, and 100 µg of the protein was resolved in 10% SDS-PAGE containing 0.1%
gelatin as MMP substrate. Gels were washed in renaturing buffer to remove SDS, rinsed
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in water and incubated for at least 48 h in developing buffer at 37C in a water bath with
gentle shaking. Gels were stained with 0.5% Coomassie brilliant blue for 1 h at room
temperature. MMP activity in the gel was detected as white bands against a dark blue
background.
Quantification of 5-methylcytosine
Genomic DNA was extracted from aorta and the amount of 5-methylcytosine (5-mC) was
measured by ELISA following manufacturer’s instructions (Zymo Research Corp.,
Irvine, CA, USA). Values are presented as mean ± SEM as percent of 5-mC
Statistical Analysis
Statistical analysis was done using Primer of Biostatistics 7.0 (McGraw-Hill, New York,
NY). One-way analysis of variance (ANOVA) followed by Bonferroni Correction was
used for comparison between the experimental groups. Differences were considered
significant when p < 0.05. Values are presented as mean ± SEM (n ≥ 4).
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Results
Effect of Aza on physiological parameters
The body and heart weights of CBS+/- (HHcy) mice were lower than the WT groups
(Figure 18). A significant increase was noticed following Aza treatment. The plasma Hcy
level (Figure 19) was higher in CBS+/- mice when compared to WT groups. This can be
explained from decreased SAM: SAH due to decreased levels of SAM and increased
levels of SAH, precursors of Hcy in CBS+/- mice when compared to WT mice (Figure
20). Following Aza treatment, SAM: SAH ratio was increased causing a decrease in
plasma Hcy levels in CBS+/- mice. The baseline systolic, diastolic (Figure 21) and mean
blood pressures (Figure 22) in CBS +/- mice were higher compared to WT groups. After
4 weeks of Aza treatment, a significant decrease was observed in the BP of CBS+/- mice.
Wall-to-lumen ratio and Resistivity Index
HHcy causes aortic vessel remodeling. To analyze the structural changes in the aorta, we
measured the lumen diameter and wall thickness of the ascending aorta and lumen
diameter of abdominal aorta. The wall-to-lumen ratio of ascending aorta in CBS+/- mice
was increased compared to WT groups (Figure 23). Similarly, the diameter of abdominal
aorta in CBS+/- mice was significantly decreased from WT and WT + Aza mice (Figure
25). After Aza treatment, the wall-to-lumen ratio of the ascending aorta decreased and the
lumen diameter of abdominal aorta increased in CBS+/- mice and was similar to WT
groups. Resistive index (RI) is a measure of the resistance of the vessel to blood flow.
The RI of ascending (Figure 24) and abdominal aortas (Figure 26) were increased in
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CBS+/- mice compared to WT groups and significantly decreased following Aza
treatment.
Aortic response to Phenylephrine, Acetylcholine and Sodium Nitroprusside
To evaluate effect of Aza on aortic function, the response of aortic rings from the
experimental groups to vasoconstriction and vasorelaxation in response to Phe and Ach
respectively, was tested in a dose-dependent manner. Aortas from CBS+/- mice were
nearly three-fold and seven-fold less responsive to Phe (Figure 27) and Ach (Figure 28)
compared to WT groups. Similarly, endothelium-independent relaxation to maximum
concentration of SNP was reduced by three-fold (Figure 29) in CBS+/- mice compared to
WT groups. Aza treatment restored the aortic responses to Phe, Ach and SNP so that they
were similar to WT groups.
Effect of Aza on collagen deposition
Collagen deposition was quantified in the aorta as an indication of vascular stiffness. WT
groups without or with Aza showed normal blue intensity, whereas, increased intensity
was observed in CBS+/- mice suggesting increased collagen deposition in the adventitia
(Figure 30). Aza treatment reduced total collagen content by 2.4-fold compared to its
untreated control. Under polarized light filter, picrosirius red stain shows type I collagen
as yellow and type III as a green color (Figure 31). Type I and III collagen from WT
without Aza treatment was considered normal and used for further analysis. Aorta from
WT+Aza did not differ from its control (Figure 31). In contrast, CBS+/- mice showed
3.8-fold increase in type I and a 4.5-fold increase in type III collagen compared to
untreated WT mice (Figure 31). Following treatment with Aza in CBS+/- mice type I
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collagen decreased by two-fold and type III by 1.5-fold compared to untreated CBS+/mice (Figure 31).
DNMT1 inhibition decreases expression of ECM remodeling and Hcy synthesis and
triggers Hcy remethylation
To examine effects of Aza treatment on the expression of proteins involved in Hcy
metabolism, we measured the expression of MTHFR, SAHH and Hcy by
immunostaining. There was an eight-fold increase in Hcy and two-fold increase in SAHH
expression (Figure 32) in CBS+/- mice compared to WT groups. MTHFR expression was
decreased by 1.5-fold in CBS+/- mice (Figure 32) compared to WT groups. These results
suggested an up-regulation of Hcy synthesis and down-regulation of Hcy remethylation
pathway in CBS+/- mice. Aza treatment decreased the expression of Hcy and SAHH and
increased MTHFR in CBS+/- mice which were similar to WT controls. To evaluate the
expression of ECM remodeling genes, we measured the expression of MMP9 and TIMP1
(Figure 33). There was a three-fold increase in MMP9 and 2.6-fold increase in TIMP1 in
CBS+/- mice (Figure 33) compared to WT control. Following Aza treatment their levels
were reduced and were similar to WT groups. MMP9 activity in cultured SMCs was
quantified using gelatin zymography. Hcy treatment increased MMP9 activity in SMCs
and following Aza treatment, MMP9 activity was decreased following Aza treatment
(Figure 34).
Global DNA Methylation in hyperhomocysteinemia
To better understand the effect of HHcy on maintenance methylation, we measured the
expression of DNMT1 in all the groups. There was a three-fold increase in DNMT1
63

expression in CBS+/- mice compared to WT controls, which was normalized by Aza
treatment (Figure 35). Similarly there was an increase in DNMT1 and 3b expression in
Hcy treated SMCs which was reduced after treatment with Aza (Figure 36). To determine
the overall methylation levels in aorta during HHcy, we measured 5-methylcytosine (5mC) from the extracted DNA. As shown in Figure 37, we observed a significant increase
in methylation levels in CBS+/- mice compared to WT groups. Following treatment with
Aza there was a significant reduction in the CBS+/- mice compared to its control. There
was an increase in global methylation levels in Hcy treated SMCs. Following Aza
treatment, methylation levels were decreased (Figure 38).
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Figure 18: Effect of Aza treatment on gravimetric parameters. Bar graph
representing gravimetric data i.e. body and heart weight. Data are shown as mean±SEM.
n=6; * p < 0.05 vs. WT and WT+Aza; † p < 0.05 vs. CBS

65

16

*

14

[Hcy] (uM)

12

†

10
8
6
4

2
0

WT

WT+Aza

CBS

CBS+Aza

Figure 19: Aza treatment normalized plasma Hcy levels. Bar graph representing
plasma Hcy level in all groups was measured using HPLC-UV. Data are shown as
mean±SEM. n=4; * p < 0.05 vs. WT and WT+Aza; † p < 0.05 vs. CBS.
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Figure 20: Aza treatment normalized SAM/SAH ratio. Bar graphs represent plasma
SAM and SAH levels in all experimental mice were measured using HPLC-UV. Data are
shown as mean ± SEM. n=4; * p < 0.05 vs. WT and WT+Aza; † p < 0.05 vs. CBS
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Figure 21: Aza treatment normalized systolic and diastolic blood pressure in HHcy
mice. Blood Pressure was measured using tail cuff method. Line graphs represent the
systolic and diastolic blood pressure. Values are expressed as mean ± SEM. n=4; * p <
0.05 vs. WT and WT+Aza; † p < 0.05 vs. CBS
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Figure 22: Aza treatment normalized mean blood pressure in HHcy. Blood Pressure
was measured using tail cuff method. Line graphs represent the mean blood pressure.
Values are expressed as mean ± SEM. n=4; * p < 0.05 vs. WT and WT+Aza; † p < 0.05
vs. CBS
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Figure 23: Aza treatment normalized ascending aorta wall-to-lumen ratio in HHcy.
B-mode ultrasound image of ascending aorta. Wall thickness (mm) and lumen diameter
(mm) were measured by Vevo 2100 (Visual Sonics Vevo Ultra Imaging System). Bar
graphs of wall-to-lumen ratio of ascending aorta represented as mean ± SEM. n=4, * p <
0.05 vs. WT and WT+Aza; † p < 0.05 vs. CBS
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Figure 24: Aza treatment normalized ascending aorta resistive index. Pulse Wave
mode images of ascending aorta. Resistive index (RI) estimated the resistance offered by
the aorta and is calculated as (PSV-EDV)/EDV. RI was measured by Vevo 2100 (Visual
Sonics Vevo Ultra Imaging System) Bar graphs represent mean RI ± SEM in ascending
aorta. n=4, * p < 0.05 vs. WT and WT+Aza; † p < 0.05 vs. CBS
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Figure 25: Aza treatment normalized abdominal aorta lumen diameter. B-mode
ultrasound image of abdominal aorta. Lumen diameter (mm) was measured by Vevo
2100 (Visual Sonics Vevo Ultra Imaging System). Bar graphs represent the lumen
diameter of abdominal aorta represented as mean ± SEM. n=4, * p < 0.05 vs. WT and
WT+Aza; † p < 0.05 vs. CBS
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Figure 26: Aza treatment normalized abdominal aorta resistive index. Pulse Wave
mode images of abdominal aorta. Resistivity Index (RI) was measured by Vevo 2100
(Visual Sonics Vevo Ultra Imaging System). Bar graphs represent mean RI ± SEM in
ascending aorta. n=4, * p < 0.05 vs. WT and WT+Aza; † p < 0.05 vs. CBS
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Figure 27: Aza treatment improved aortic response to Phe. Aorta was extracted from
experimental mice (WT, WT+Aza, CBS, CBS+Aza) following protocol described in
Materials and Methods. Aortic rings were mounted in myobath containing Kreb’s
solution. The rings were treated with phenylephrine (Phe) in a dose dependent manner as
described in Materials and Methods. Data are shown as n=4; * p < 0.05 vs. WT and
WT+Aza; † p < 0.05 vs. CBS
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Figure 28: Aza treatment improved aortic response to Ach. Aorta was extracted from
experimental mice (WT, WT+Aza, CBS, CBS+Aza) following protocol described in
Materials and Methods. Aortic rings were mounted in myobath containing Kreb’s
solution. Rings were treated with acetylcholine (Ach) in a dose dependent manner as
described in Materials and Methods. Data are shown as n=4; * p < 0.05 vs. WT and
WT+Aza; † p < 0.05 vs. CBS
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Figure 29: Aza treatment improved aortic response to SNP. Aorta was extracted from
experimental mice (WT, WT+Aza, CBS, CBS+Aza) following protocol described in
Materials and Methods. Aortic rings were mounted in myobath containing Kreb’s
solution. Rings were treated with sodium nitroprusside (SNP) in a dose dependent
manner as described in Materials and Methods. Data are shown as n=4; * p < 0.05 vs.
WT and WT+Aza; † p < 0.05 vs. CBS
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Figure 30: Collagen expression was decreased post Aza treatment. Collagen is
stained as dark blue. Original image, x 20 magnification. Bar graph represents the %
mean intensity ± SEM of blue color in the aorta. n=4, * p < 0.05 vs. WT and WT+Aza; †
p < 0.05 vs. CBS
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Figure 31 A: Aza treatment decreased collagen I and III in HHcy. Picrosirius red
staining for type I and type III collagen (yellow and green colors represent type I and type
III collagen respectively), Original image, x 20 magnification

78

Type I collagen
(% change )

500

*

400
300

†, ‡

200
100
0

WT

WT+Aza

Type III collagen
(% change)

600

CBS

CBS+Aza

*

500
400

†, *

300
200
100

0

WT

WT+Aza

CBS

CBS+Aza

Figure 31 B: Aza treatment decreased collagen I and III in HHcy. Bar graph
represents % mean intensity ± SEM of yellow (Type I) and green (Type III) color in
aorta. n=4. * p < 0.05 vs. WT and WT+Aza; † p < 0.05 vs. CBS; ‡ p < 0.05 vs. WT.
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Figure 32A: Aza treatment decreases Hcy accumulation. The protein expressions of
SAHH, Hcy and MTHFR were measured. Expression of MTHFR and SAHH are shown
as green fluorescence and expression of Hcy is seen as red fluorescence. Original image,
Hcy x 20 magnification, SAHH, MTHFR, x 10 magnification
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Figure 32B: Aza treatment decreases Hcy accumulation. Bar graph representations of
the IHC images. Y-axis represents % change mean intensity ± SEM. n=4; * p < 0.05 vs.
WT, WT+Aza and CBS+Aza; † p < 0.05 vs. WT, WT+Aza and CBS+Aza;  p< 0.05 vs.
WT, WT+Aza
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Figure 33A: Aza treatment normalizes the expression of MMP9 and TIMP1 in
HHcy. The protein expressions of MMP9, TIMP1 were measured. Expression of MMP9
and TIMP1 are seen as red fluorescence. Original images, x 10 magnification
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Figure 33B: Aza treatment normalizes the expression of MMP9 and TIMP1 in
HHcy. Bar graph representations of the IHC images. Y-axis represents % change mean
intensity ± SEM. n=4; * p < 0.05 vs. WT, WT+Aza and CBS+Aza; † p < 0.05 vs. WT,
WT+Aza and CBS+Aza; ‡ p < 0.05 vs. WT and WT+Aza.
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Figure 34: Aza treatment decreased MMP9 activity in Hcy treated SMCs. Gelatin
zymography was done to analyze the activity of MMP9 in Aza and Hcy treated SMCs.
Bar graph is expressed as mean intensity ± SEM * p < 0.05 vs. Ctrl and Aza, † p<0.05 vs
Hcy
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Figure 35: Aza treatment decreases DNMT1 in HHcy. The protein expressions of
DNMT1 were measured. Expression of DNMT1 is shown as green fluorescence. Bar
graph representations of the IHC images. Y-axis represents % change mean intensity ±
SEM. n=4; * p < 0.05 vs. WT, WT+Aza and CBS+Aza; Original image x 10
magnification
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Figure 36: Aza treatment decreases DNMT1, 3b in Hcy treated SMCs.
Immunoblotting of DNMT1, 3a and 3b. Bar graphs show the relative expression of
DNMT1, 3a and 3b over controls, after normalization with GAPDH. The data are shown
as mean ± SEM. n=4; * , † p < 0.05 vs. ctrl, Aza and Hcy + Aza.
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Figure 37: Aza treatment decreases global methylation levels in aorta. Overall
methylation levels were measured using ELISA. The bar graphs represent the mean %5mC ± SEM; n=4, * p < 0.05 vs. WT and WT+Aza; † p < 0.05 vs. CBS.
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Figure 38: Aza treatment decreases global methylation in SMCs. Overall methylation
levels were measured using ELISA. The bar graphs represent the mean %5-mC ± SEM;
n=5, * p < 0.05 vs. Ctrl and Aza; † p < 0.05 vs. Hcy.
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Discussion
HHcy plays a critical role in the development of various aortic diseases [154-157]. HHcy
induces the expression of MMPs involved in ECM metabolism, promoting aortic
remodeling resulting in arterial hypertension [141]. Epigenetic mechanisms such as DNA
methylation are known to control the expression of ECM components [158]. Although
various studies report aberrant DNA methylation pattern in early stages of atherosclerosis
[159] and aortic aneurysm [29], the role of DNA hypermethylation on aortic remodeling
and arterial hypertension in HHcy still remains unclear. In the recent years, epigenetic
inhibitors are being used as therapeutic agents in various cancer drug trials [151] . Our
study provides new insights into the mechanism and the use of epigenetic inhibitors as
therapeutic option in hypertension associated aortic pathologies.
In the present study, we used CBS+/- mice as HHcy model. In a previous report, Gupta et
al., demonstrate that CBS deficient mice have decreased fat mass due to reduction in
lipogenesis [160]. Our observation of reduced body weight in CBS+/- mice supported
this earlier finding. Plasma Hcy level is an important predictor of pulse pressure in
hypertensive subjects [161]. In the previous study, increased plasma Hcy in CBS+/- mice
was associated with elevated systolic, diastolic and mean blood pressure. Evidence from
earlier studies suggest that lowering plasma Hcy level by supplemental vitamins such as
folic acid, B6 and B12 is effective in delaying the formation of atherosclerotic plaques
[162]. Our results showed that Aza lowers plasma Hcy in CBS+/- mice to normal levels.
Plasma levels of S-adenosyl homocysteine (SAH), precursor of Hcy, is correlated to Hcy
levels [125]. S-adenosyl methionine (SAM) and SAH levels were decreased and
increased respectively in HHcy mice. Aza treatment reversed this effect in CBS+/- mice.
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During HHcy, the conversion of SAM to SAH liberates excess methyl groups which are
used in methylating substrates including DNA and proteins. Indeed hypermethylation of
gene promoters occurred in hypertension. For example, sulfatase 1, (SULF1) gene, an
endosulfatase, has been reported to be hypermethylated in hypertensive subjects [163]. In
our study, we showed that Aza treatment in hypertensive CBS+/- mice restored systolic,
diastolic and mean blood pressure to normal levels, which suggested an important role for
hypermethylation in HHcy associated hypertension.
Excessive accumulation of ECM proteins in HHcy causes hypertrophic vascular
remodeling by increasing the wall thickness and decreasing lumen diameter. [62, 164]. In
the present study, ultrasound examination revealed increased wall-to-lumen ratio of
ascending aorta and decreased lumen diameter of abdominal aorta in CBS+/- mice. In an
earlier study from our lab, treatment of CBS+/- mice with SAH hydrolase inhibitor,
(Deazaadenosine, DZA), decreased systolic blood pressure without a change in the aortic
wall-to-lumen ratio within the first week of treatment [141]. This result suggested that the
reduction in systolic blood pressure was secondary to reduction in cardiac output
preceding structural remodeling [141]. In the present study, we show that Aza treatment
decreased BP at three weeks suggesting a significant role for epigenetic mechanism in
aortic remodeling during HHcy-induced hypertension. The reduction in blood pressure
(systolic, diastolic and mean) was associated with a reduction in wall-to-lumen ratio of
ascending aorta and increase in lumen diameter of abdominal aorta. Resistive index (RI)
of aorta was measured as an indication of resistance to blood flow. In previous literature,
a positive correlation was reported for carotid artery RI and atherosclerosis [165]. In our
study, increased RI in CBS+/- suggested vascular stiffness and was associated with
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increased MMP9 activity and TIMP1 expression. The increase in TIMP1 appears to be
compensatory to increased MMP9. Consistent with our findings, increased MMP9 and
TIMP1 occurs in pathologies such as neonatal encephalopathy [166] and aortic aneurysm
[167]. Our results demonstrated that Aza treatment reduces collagen deposition and also
decreases MMP9 and TIMP1 expression in HHcy. The reduction in the wall-to-lumen
ratio and RI upon Aza treatment suggested mitigation of aortic ECM remodeling.
Although previous studies reported no significant changes in smooth muscle contraction
(Phe) [168] or endothelium-independent relaxation (SNP) [169] between WT and HHcy
mice, we saw a significant decrease in the aortic response to Phe, Ach and SNP in HHcy
mice. Consistent with our findings, Tyagi et al [170] reported that HHcy mice showed
decreased response to vasoconstrictor (Endothelin-1) compared to controls. In the present
study, the impairment of vessel function suggests endothelial and smooth muscle
dysfunction and vascular stiffness. Aza treatment improved vascular response to Phe,
Ach and SNP in HHcy and also reduced vessel stiffness as indicated by reduction of
collagen deposition. This suggested that DNMT1 inhibition improved aortic function
during HHcy thereby mitigates hypertension.
Hcy is derived from de-methylation of dietary methionine. S-adenosyl homocysteine
hydrolase (SAHH) plays a major role in the synthesis of Hcy from S-adenosyl
homocysteine. Following synthesis, Hcy has two fates: a) transsulfuration to cysteine
aided by CBS and b) remethylation to methionine by MTHFR in the folate metabolism
pathway [149]. Previous study shows that in HHcy, betaine Hcy methyltransferase
(BHMT) and formation of 5-methyltetrahydrofolate by methylenetetrahydrofolate
reductase (MTHFR) is inhibited [171]. The fate of homocysteine in the body is controlled
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by a balance between the remethylation and transsulfuration pathways. During high
methionine diet, Hcy catabolism is increased favoring transsulfuration over
remethylation. In contrast, with a low methionine diet the remethylation pathway was
favored compared to transsulfuration [149]. Since CBS is a key enzyme in Hcy
metabolism, genetic mutations in CBS [172] and dietary deficiency of amino acids such
as methionine or taurine and vitamins (folate and B12) can affect the plasma Hcy
concentrations. In a recent study, Tang et al demonstrated that when WT and transgenic
mice expressing human CBS were fed a low methionine diet, the protein levels of CBS in
the liver and the activity were decreased to conserve methionine levels in the body [173].
In the transsulfuration pathway, Hcy is catabolized to yield taurine which reduces total
serum cholesterol by lowering very low density lipoprotein (VLDL) and low density
lipoprotein (LDL) [174]. When CBS+/- mice were fed taurine deficient diet, there was an
upregulation of CBS monoallele along with a reduction in total serum cholesterol levels.
These studies suggest the impact of enzymes involved in Hcy metabolism such as CBS,
SAHH and MTHFR in maintaining plasma Hcy levels. In the present study,
immunostaining analysis revealed an upregulation of SAHH and Hcy expression and
downregulation of MTHFR in the aorta from HHcy mice. Also, a previous study suggests
a negative correlation between the concentration of SAH and MTHFR expression [125].
Upon treatment with Aza, there was a reduction in the SAHH expression and increase in
MTHFR suggesting increased remethylation to reduce plasma Hcy levels.
Previous reports in the literature link HHcy to both global hypermethylation [175] and
hypomethylation [176]. A study by Zhang et al., showed that the effect of Hcy on
methylation patterns of gene promoters was dependent on Hcy concentration. HHcy is
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known to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH2), an
enzyme involved in the nitric oxide synthase pathway, causing endothelial dysfunction.
Previous studies report hypermethylation of DDAH2 promoters in HHcy [177]. Also, an
earlier study in our lab, showed increased DNMT1 expression in HHcy mice suggesting
hypermethylation [37]. In the present study, we confirmed global hypermethylation by
quantitating %5-mC in HHcy mice aorta and Hcy treated SMCs. Treatment with Aza
decreased the expression of DNMT1, 3b and also reduced global methylation levels.
Although previous results suggest a positive correlation between SAM/SAH ratio and
DNA methylation [178], we found DNA hypermethylation with decreased SAM/SAH
ratio in Hcy mice. The decrease in SAM/SAH ratio suggests an increased Hcy production
accompanied by an increased availability of methyl groups for DNA methylation.
An approach to alleviate HHcy mediated aortic pathology is to lower plasma Hcy levels.
Although folic acid supplementation decreases Hcy level to prevent disease progression,
it is unable to reverse the existing HHcy induced aortic pathology, termed as Hcy
memory effect [178]. The present study for the first time provides evidence that
epigenetic DNMT inhibitor can be a potential therapeutic agent independently or in
combination with other therapies such as folic acid in aortic diseases.
In conclusion, HHcy promotes pathological aortic remodeling and endothelial
dysfunction leading to arterial hypertension. Inhibition of DNMT1, using Aza,
ameliorates Hcy level and reduces high blood pressure. Aza appears to mediate its action
by modifying the expression of enzymes involved in Hcy metabolism and ECM proteins
to reduce vascular stiffness thus improving vascular function.
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CHAPTER VI
SUMMARY, CONCLUSION AND FUTURE DIRECTIONS
Cardiovascular diseases are the leading cause of death worldwide. HHcy is
identified as one of the primary risk factors for cardiovascular diseases such as diseases
of the aorta [5, 139]. An elevation of the plasma Hcy level correlates with blood pressure
in human subjects with methionine loading [108]. Arterial stiffness and vascular
dysfunction are the characteristic features that contribute to cardiovascular diseases such
as atherosclerosis, which causes resistance to blood flow leading to hypertension [20].
Previous studies suggest an increased accumulation of ECM components such as
collagen and MMPs in cardiovascular diseases causing ECM remodeling [61]. Epigenetic
modifications such as DNA methylation and histone modifications regulate the
expression of cellular proteins. Furthermore, evidence suggests a role of DNA
methylation in HHcy associated pathologies. Therefore, epigenetic inhibitor therapies are
currently being considered as a promising approach in various diseases.
In the first set of experiments it was found that in CBS+/- mice, increased levels
of plasma Hcy caused an increase in the synthesis and accumulation of ECM
components. Increased collagen deposition and decreased elastin levels contributed to
aortic stiffness providing resistance to the incoming blood flow. This narrowing of blood
vessels contributes to the development of arterial hypertension. Epigenetic mechanisms
played a major role in regulating the transcription of these ECM remodeling genes.
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HHcy triggers epigenetic changes by increasing the expression of enzymes involved in
epigenetic modifications such as DNA methylation (DNMT1, 3a, MBD2) and Histone
methylation (H3K9). These changes contributed to increased genome-wide global DNA
methylation levels thereby regulating various pathways.
In the second set of studies, to ascertain the effect of DNA methylation in aortic
remodeling in HHcy, CBS+/- mice were treated with an epigenetic inhibitor, Aza. Aza
treatment decreased global hypermethylation by inhibiting DNMT1 and hence lowered
plasma Hcy levels in CBS+/- mice. Aza treatment also decreased ECM remodeling by
lowering the expression of MMP9 and deposition of collagen in the aorta wall causing
decreased wall to lumen ratio and resistive index thus mitigating hypertension in HHcy
mice. Hence, treatment with epigenetic inhibitors is a possible therapeutic approach to
prevent HHcy associated pathological remodeling.
Future Directions:
Hypertension-induced aortic remodeling is a complex process involving enzymes that
synthesize ECM components and their regulators such as MMPs and TIMPs. This study
mainly focused on the effect of an epigenetic inhibitor, Aza, on ECM remodeling
proteins (MMP9, TIMP1, Collagen) and Hcy metabolism enzymes (SAHH, MTHFR) in
the aorta. However, as the enzymes involved in Hcy metabolism are located in other
organs such as kidney and liver, additional studies are required to quantitate the specific
effect of Aza on individual enzymes involved in Hcy metabolism. Although this study
provides evidence of impairment in vascular function in HHcy mice and its improvement
with Aza, understanding the mechanism by which HHcy affects promoter methylation of
95

individual genes involved in pathways such as nitric oxide synthase pathway requires
elucidation.

96

REFERENCES
1.

Lopez, A.D., C.D. Mathers, M. Ezzati, D.T. Jamison, and C.J. Murray, Global and
regional burden of disease and risk factors, 2001: systematic analysis of population
health data. Lancet, 2006. 367(9524): p. 1747-57.

2.

Paradis, G. and A. Chiolero, The cardiovascular and chronic diseases epidemic in lowand middle-income countries: a global health challenge. J Am Coll Cardiol, 2011.
57(17): p. 1775-7.

3.

Go, A.S., D. Mozaffarian, V.L. Roger, E.J. Benjamin, J.D. Berry, M.J. Blaha, S. Dai, E.S.
Ford, C.S. Fox, S. Franco, H.J. Fullerton, C. Gillespie, S.M. Hailpern, J.A. Heit, V.J.
Howard, M.D. Huffman, S.E. Judd, B.M. Kissela, S.J. Kittner, D.T. Lackland, J.H.
Lichtman, L.D. Lisabeth, R.H. Mackey, D.J. Magid, G.M. Marcus, A. Marelli, D.B.
Matchar, D.K. McGuire, E.R. Mohler, 3rd, C.S. Moy, M.E. Mussolino, R.W. Neumar, G.
Nichol, D.K. Pandey, N.P. Paynter, M.J. Reeves, P.D. Sorlie, J. Stein, A. Towfighi, T.N.
Turan, S.S. Virani, N.D. Wong, D. Woo, M.B. Turner, C. American Heart Association
Statistics, and S. Stroke Statistics, Heart disease and stroke statistics--2014 update: a
report from the american heart association. Circulation, 2014. 129(3): p. e28-e292.

4.

Svensson, L.G. and E.R. Rodriguez, Aortic organ disease epidemic, and why do balloons
pop? Circulation, 2005. 112(8): p. 1082-4.

5.

Giusti, B., R. Marcucci, I. Lapini, I. Sestini, M. Lenti, M. Yacoub, and G. Pepe, Role of
hyperhomocysteinemia in aortic disease. Cell Mol.Biol.(Noisy.-le-grand), 2004. 50(8): p.
945-952.

6.

Chambers, J.C., A. McGregor, J. Jean-Marie, and J.S. Kooner, Acute
hyperhomocysteinaemia and endothelial dysfunction. Lancet, 1998. 351(9095): p. 36-7.

7.

Tyagi, S.C., Homocysteine redox receptor and regulation of extracellular matrix
components in vascular cells. Am J Physiol, 1998. 274(2 Pt 1): p. C396-405.
97

8.

Liu, Z., H. Luo, L. Zhang, Y. Huang, B. Liu, K. Ma, J. Feng, J. Xie, J. Zheng, J. Hu, S.
Zhan, Y. Zhu, Q. Xu, W. Kong, and X. Wang, Hyperhomocysteinemia exaggerates
adventitial inflammation and angiotensin II-induced abdominal aortic aneurysm in mice.
Circ Res, 2012. 111(10): p. 1261-73.

9.

Chen, Z., A.C. Karaplis, S.L. Ackerman, I.P. Pogribny, S. Melnyk, S. Lussier-Cacan,
M.F. Chen, A. Pai, S.W. John, R.S. Smith, T. Bottiglieri, P. Bagley, J. Selhub, M.A.
Rudnicki, S.J. James, and R. Rozen, Mice deficient in methylenetetrahydrofolate
reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with
neuropathology and aortic lipid deposition. Hum Mol Genet, 2001. 10(5): p. 433-43.

10.

Jiang, N., G. Du, E. Tobias, J.G. Wood, R. Whitaker, N. Neretti, and S.L. Helfand,
Dietary and genetic effects on age-related loss of gene silencing reveal epigenetic
plasticity of chromatin repression during aging. Aging (Albany NY), 2013. 5(11): p.
813-24.

11.

Lee, W.J., J.Y. Shim, and B.T. Zhu, Mechanisms for the inhibition of DNA
methyltransferases by tea catechins and bioflavonoids. Mol Pharmacol, 2005. 68(4): p.
1018-30.

12.

Mathers, J.C., G. Strathdee, and C.L. Relton, Induction of epigenetic alterations by
dietary and other environmental factors. Adv Genet, 2010. 71: p. 3-39.

13.

Liu, H., Y. Zhou, S.E. Boggs, S.A. Belinsky, and J. Liu, Cigarette smoke induces
demethylation of prometastatic oncogene synuclein-gamma in lung cancer cells by
downregulation of DNMT3B. Oncogene, 2007. 26(40): p. 5900-10.

14.

Kalani, A., P.K. Kamat, S.C. Tyagi, and N. Tyagi, Synergy of homocysteine, microRNA,
and epigenetics: a novel therapeutic approach for stroke. Mol Neurobiol, 2013. 48(1): p.
157-68.

15.

Mack, G.S., To selectivity and beyond. Nat Biotechnol, 2010. 28(12): p. 1259-66.

16.

Aronberg, D.J., H.S. Glazer, K. Madsen, and S.S. Sagel, Normal thoracic aortic
diameters by computed tomography. J Comput Assist Tomogr, 1984. 8(2): p. 247-50.

98

17.

Dollar, A.L., Anatomy of the aorta. Diseases of the aorta, ed. J.L. Jr. 1994: Lea and
Febiger.

18.

Ward, C., Clinical significance of the bicuspid aortic valve. Heart, 2000. 83(1): p. 81-5.

19.

Michelena, H.I., A.D. Khanna, D. Mahoney, E. Margaryan, Y. Topilsky, R.M. Suri, B.
Eidem, W.D. Edwards, T.M. Sundt, III, and M. Enriquez-Sarano, Incidence of aortic
complications in patients with bicuspid aortic valves. JAMA, 2011. 306(10): p. 11041112.

20.

Alexander, R.W., Theodore Cooper Memorial Lecture. Hypertension and the
pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial
inflammatory response: a new perspective. Hypertension, 1995. 25(2): p. 155-61.

21.

Brensike, J.F., R.I. Levy, S.F. Kelsey, E.R. Passamani, J.M. Richardson, I.K. Loh, N.J.
Stone, R.F. Aldrich, J.W. Battaglini, D.J. Moriarty, and et al., Effects of therapy with
cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II
Coronary Intervention Study. Circulation, 1984. 69(2): p. 313-24.

22.

Kawamori, R., Y. Yamasaki, H. Matsushima, H. Nishizawa, K. Nao, H. Hougaku, H.
Maeda, N. Handa, M. Matsumoto, and T. Kamada, Prevalence of carotid atherosclerosis
in diabetic patients. Ultrasound high-resolution B-mode imaging on carotid arteries.
Diabetes Care, 1992. 15(10): p. 1290-4.

23.

Libby, P., Inflammation in atherosclerosis. Nature, 2002. 420(6917): p. 868-74.

24.

Libby, P., P.M. Ridker, and A. Maseri, Inflammation and atherosclerosis. Circulation,
2002. 105(9): p. 1135-43.

25.

Golledge, J. and P.E. Norman, Atherosclerosis and abdominal aortic aneurysm: cause,
response, or common risk factors? Arterioscler Thromb Vasc Biol, 2010. 30(6): p. 10757.

26.

Wong, D.R., W.C. Willett, and E.B. Rimm, Smoking, hypertension, alcohol consumption,
and risk of abdominal aortic aneurysm in men. Am J Epidemiol, 2007. 165(7): p. 838-45.

27.

Strachan, D.P., Predictors of death from aortic aneurysm among middle-aged men: the
Whitehall study. Br J Surg, 1991. 78(4): p. 401-4.
99

28.

Brunelli, T., D. Prisco, S. Fedi, A. Rogolino, A. Farsi, R. Marcucci, B. Giusti, C. Pratesi,
R. Pulli, G.F. Gensini, R. Abbate, and G. Pepe, High prevalence of mild
hyperhomocysteinemia in patients with abdominal aortic aneurysm. J Vasc Surg, 2000.
32(3): p. 531-6.

29.

Krishna, S.M., A.E. Dear, P.E. Norman, and J. Golledge, Genetic and epigenetic
mechanisms and their possible role in abdominal aortic aneurysm. Atherosclerosis, 2010.
212(1): p. 16-29.

30.

Paulo, N., J. Cascarejo, and L. Vouga, Syphilitic aneurysm of the ascending aorta.
Interact Cardiovasc Thorac Surg, 2012. 14(2): p. 223-5.

31.

Dietz, H.C., Marfan Syndrome, in GeneReviews, R.A. Pagon, M.P. Adam, T.D. Bird,
C.R. Dolan, C.T. Fong, and K. Stephens, Editors. 1993: Seattle (WA).

32.

Juang, D., A.C. Braverman, and K. Eagle, Cardiology patient pages. Aortic dissection.
Circulation, 2008. 118(14): p. e507-10.

33.

Hillenbrand, R., A. Hillenbrand, F. Liewald, and J. Zimmermann, Hyperhomocysteinemia
and recurrent carotid stenosis. BMC Cardiovasc Disord, 2008. 8: p. 1.

34.

James, S.J., S. Melnyk, M. Pogribna, I.P. Pogribny, and M.A. Caudill, Elevation in Sadenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for
homocysteine-related pathology. J.Nutr., 2002. 132(8 Suppl): p. 2361S-2366S.

35.

Nygard, O., J.E. Nordrehaug, H. Refsum, P.M. Ueland, M. Farstad, and S.E. Vollset,
Plasma homocysteine levels and mortality in patients with coronary artery disease. N
Engl J Med, 1997. 337(4): p. 230-6.

36.

Giusti, B., M.C. Porciani, T. Brunelli, L. Evangelisti, S. Fedi, G.F. Gensini, R. Abbate, G.
Sani, M. Yacoub, and G. Pepe, Phenotypic variability of cardiovascular manifestations in
Marfan Syndrome. Possible role of hyperhomocysteinemia and C677T MTHFR gene
polymorphism. Eur Heart J, 2003. 24(22): p. 2038-45.

37.

Narayanan, N., N. Tyagi, A. Shah, S. Pagni, and S.C. Tyagi, Hyperhomocysteinemia
during aortic aneurysm, a plausible role of epigenetics. Int J Physiol Pathophysiol
Pharmacol, 2013. 5(1): p. 32-42.
100

38.

Wong, Y.Y., J. Golledge, L. Flicker, K.A. McCaul, G.J. Hankey, F.M. van Bockxmeer,
B.B. Yeap, and P.E. Norman, Plasma total homocysteine is associated with abdominal
aortic aneurysm and aortic diameter in older men. J Vasc Surg, 2013. 58(2): p. 364-70.

39.

Alessio, A.C., J.M. Annichino-Bizzacchi, S.P. Bydlowski, M.N. Eberlin, A.P. Vellasco,
and N.F. Hoehr, Polymorphisms in the methylenetetrahydrofolate reductase and
methionine synthase reductase genes and homocysteine levels in Brazilian children. Am J
Med Genet A, 2004. 128A(3): p. 256-60.

40.

Mudd, S.H., J.D. Finkelstein, F. Irreverre, and L. Laster, Homocystinuria: An Enzymatic
Defect. Science, 1964. 143(3613): p. 1443-5.

41.

Choumenkovitch, S.F., J. Selhub, P.J. Bagley, N. Maeda, M.R. Nadeau, D.E. Smith, and
S.W. Choi, In the cystathionine beta-synthase knockout mouse, elevations in total plasma
homocysteine increase tissue S-adenosylhomocysteine, but responses of Sadenosylmethionine and DNA methylation are tissue specific. J Nutr, 2002. 132(8): p.
2157-60.

42.

McCully, K.S., Vascular pathology of homocysteinemia: implications for the
pathogenesis of arteriosclerosis. Am J Pathol, 1969. 56(1): p. 111-28.

43.

McCully, K.S., Homocysteine and vascular disease. Nat Med, 1996. 2(4): p. 386-9.

44.

Stamler, J.S., J.A. Osborne, O. Jaraki, L.E. Rabbani, M. Mullins, D. Singel, and J.
Loscalzo, Adverse vascular effects of homocysteine are modulated by endotheliumderived relaxing factor and related oxides of nitrogen. J Clin Invest, 1993. 91(1): p. 30818.

45.

Starkebaum, G. and J.M. Harlan, Endothelial cell injury due to copper-catalyzed
hydrogen peroxide generation from homocysteine. J Clin Invest, 1986. 77(4): p. 1370-6.

46.

Radomski, M.W. and E. Salas, Nitric oxide--biological mediator, modulator and factor of
injury: its role in the pathogenesis of atherosclerosis. Atherosclerosis, 1995. 118 Suppl:
p. S69-80.

101

47.

Stuhlinger, M.C., P.S. Tsao, J.H. Her, M. Kimoto, R.F. Balint, and J.P. Cooke,
Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric
dimethylarginine. Circulation, 2001. 104(21): p. 2569-75.

48.

Tawakol, A., T. Omland, M. Gerhard, J.T. Wu, and M.A. Creager,
Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent
vasodilation in humans. Circulation, 1997. 95(5): p. 1119-21.

49.

Desai, A., H.A. Lankford, and J.S. Warren, Homocysteine augments cytokine-induced
chemokine expression in human vascular smooth muscle cells: implications for
atherogenesis. Inflammation, 2001. 25(3): p. 179-86.

50.

Poddar, R., N. Sivasubramanian, P.M. DiBello, K. Robinson, and D.W. Jacobsen,
Homocysteine induces expression and secretion of monocyte chemoattractant protein-1
and interleukin-8 in human aortic endothelial cells: implications for vascular disease.
Circulation, 2001. 103(22): p. 2717-23.

51.

Wang, G., Y.L. Siow, and K. O, Homocysteine induces monocyte chemoattractant
protein-1 expression by activating NF-kappaB in THP-1 macrophages. Am J Physiol
Heart Circ Physiol, 2001. 280(6): p. H2840-7.

52.

Wang, G. and K. O, Homocysteine stimulates the expression of monocyte
chemoattractant protein-1 receptor (CCR2) in human monocytes: possible involvement of
oxygen free radicals. Biochem J, 2001. 357(Pt 1): p. 233-40.

53.

Alexandru, N., I. Jardin, D. Popov, M. Simionescu, J. Garcia-Estan, G.M. Salido, and
J.A. Rosado, Effect of homocysteine on calcium mobilization and platelet function in type
2 diabetes mellitus. J Cell Mol Med, 2008. 12(5B): p. 2015-26.

54.

Hirano, K., T. Ogihara, M. Miki, H. Yasuda, H. Tamai, N. Kawamura, and M. Mino,
Homocysteine induces iron-catalyzed lipid peroxidation of low-density lipoprotein that is
prevented by alpha-tocopherol. Free Radic Res, 1994. 21(5): p. 267-76.

55.

Blom, H.J., H.A. Kleinveld, G.H. Boers, P.N. Demacker, H.L. Hak-Lemmers, M.T. Te
Poele-Pothoff, and J.M. Trijbels, Lipid peroxidation and susceptibility of low-density
lipoprotein to in vitro oxidation in hyperhomocysteinaemia. Eur J Clin Invest, 1995.
25(3): p. 149-54.
102

56.

Voutilainen, S., J.D. Morrow, L.J. Roberts, 2nd, G. Alfthan, H. Alho, K. Nyyssonen, and
J.T. Salonen, Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine
levels. Arterioscler Thromb Vasc Biol, 1999. 19(5): p. 1263-6.

57.

Tsai, J.C., M.A. Perrella, M. Yoshizumi, C.M. Hsieh, E. Haber, R. Schlegel, and M.E.
Lee, Promotion of vascular smooth muscle cell growth by homocysteine: a link to
atherosclerosis. Proc Natl Acad Sci U S A, 1994. 91(14): p. 6369-73.

58.

Harker, L.A., J.M. Harlan, and R. Ross, Effect of sulfinpyrazone on homocysteineinduced endothelial injury and arteriosclerosis in baboons. Circ Res, 1983. 53(6): p. 7319.

59.

McDonald, T.P., T.T. Odell, Jr., and D.G. Gosslee, Platelet Size in Relation to Platelet
Age. Proc Soc Exp Biol Med, 1964. 115: p. 684-9.

60.

Uhlemann, E.R., J.H. TenPas, A.W. Lucky, J.D. Schulman, S.H. Mudd, and N.R.
Shulman, Platelet survival and morphology in homocystinuria due to cystathionine
synthase deficiency. N Engl J Med, 1976. 295(23): p. 1283-6.

61.

Munjal, C., S. Givvimani, N. Qipshidze, N. Tyagi, J.C. Falcone, and S.C. Tyagi,
Mesenteric vascular remodeling in hyperhomocysteinemia. Mol Cell Biochem, 2011.
348(1-2): p. 99-108.

62.

Basu, P., N. Qipshidze, S.C. Tyagi, and U. Sen, Remodeling in vein expresses arterial
phenotype in hyperhomocysteinemia. Int J Physiol Pathophysiol Pharmacol, 2011. 3(4):
p. 266-79.

63.

Shekhonin, B.V., S.P. Domogatsky, V.R. Muzykantov, G.L. Idelson, and V.S. Rukosuev,
Distribution of type I, III, IV and V collagen in normal and atherosclerotic human
arterial wall: immunomorphological characteristics. Coll Relat Res, 1985. 5(4): p. 35568.

64.

Wagenseil, J.E. and R.P. Mecham, Elastin in large artery stiffness and hypertension. J
Cardiovasc Transl Res, 2012. 5(3): p. 264-73.

65.

Greenwald, S.E., Ageing of the conduit arteries. J Pathol, 2007. 211(2): p. 157-72.

103

66.

McEniery, C.M., I.B. Wilkinson, and A.P. Avolio, Age, hypertension and arterial
function. Clin Exp Pharmacol Physiol, 2007. 34(7): p. 665-71.

67.

Marti, C.N., M. Gheorghiade, A.P. Kalogeropoulos, V.V. Georgiopoulou, A.A.
Quyyumi, and J. Butler, Endothelial dysfunction, arterial stiffness, and heart failure. J
Am Coll Cardiol, 2012. 60(16): p. 1455-69.

68.

Rubba, P., M. Mercuri, F. Faccenda, A. Iannuzzi, C. Irace, P. Strisciuglio, A. Gnasso, R.
Tang, G. Andria, M.G. Bond, and et al., Premature carotid atherosclerosis: does it occur
in both familial hypercholesterolemia and homocystinuria? Ultrasound assessment of
arterial intima-media thickness and blood flow velocity. Stroke, 1994. 25(5): p. 943-50.

69.

Gibson, J.B., N.A. Carson, and D.W. Neill, Pathological Findings in Homocystinuria. J
Clin Pathol, 1964. 17: p. 427-37.

70.

Carey, M.C., D.E. Donovan, O. FitzGerald, and F.D. McAuley, Homocystinuria. I. A
clinical and pathological study of nine subjects in six families. Am J Med, 1968. 45(1): p.
7-25.

71.

Gross, J. and C.M. Lapiere, Collagenolytic activity in amphibian tissues: a tissue culture
assay. Proc Natl Acad Sci U S A, 1962. 48: p. 1014-22.

72.

Hadler-Olsen, E., B. Fadnes, I. Sylte, L. Uhlin-Hansen, and J.O. Winberg, Regulation of
matrix metalloproteinase activity in health and disease. FEBS J, 2011. 278(1): p. 28-45.

73.

Redlich, M., H. Roos, E. Reichenberg, B. Zaks, A. Grosskop, K. Bar, I, S. Pitaru, and A.
Palmon, The effect of centrifugal force on mRNA levels of collagenase, collagen type-I,
tissue inhibitors of metalloproteinases and beta-actin in cultured human periodontal
ligament fibroblasts. J.Periodontal Res., 2004. 39(1): p. 27-32.

74.

Kadoglou, N.P. and C.D. Liapis, Matrix metalloproteinases: contribution to
pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr
Med Res Opin, 2004. 20(4): p. 419-32.

75.

Suzuki, K., J.J. Enghild, T. Morodomi, G. Salvesen, and H. Nagase, Mechanisms of
activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin).
Biochemistry, 1990. 29(44): p. 10261-70.
104

76.

Visse, R. and H. Nagase, Matrix metalloproteinases and tissue inhibitors of
metalloproteinases: structure, function, and biochemistry. Circ Res, 2003. 92(8): p. 82739.

77.

Amalinei, C., I.D. Caruntu, and R.A. Balan, Biology of metalloproteinases. Rom J
Morphol Embryol, 2007. 48(4): p. 323-34.

78.

Fiskus, W., R. Rao, P. Fernandez, B. Herger, Y. Yang, J. Chen, R. Kolhe, A. Mandawat,
Y. Wang, R. Joshi, K. Eaton, P. Lee, P. Atadja, S. Peiper, and K. Bhalla, Molecular and
biologic characterization and drug sensitivity of pan-histone deacetylase inhibitorresistant acute myeloid leukemia cells. Blood, 2008. 112(7): p. 2896-905.

79.

Pyo, R., J.K. Lee, J.M. Shipley, J.A. Curci, D. Mao, S.J. Ziporin, T.L. Ennis, S.D.
Shapiro, R.M. Senior, and R.W. Thompson, Targeted gene disruption of matrix
metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal
aortic aneurysms. J.Clin.Invest, 2000. 105(11): p. 1641-1649.

80.

Kadoglou, N.P. and C.D. Liapis, Matrix metalloproteinases: contribution to
pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms.
Curr.Med.Res.Opin., 2004. 20(4): p. 419-432.

81.

Fu, X., W.C. Parks, and J.W. Heinecke, Activation and silencing of matrix
metalloproteinases. Semin Cell Dev Biol, 2008. 19(1): p. 2-13.

82.

Greene, J., M. Wang, Y.E. Liu, L.A. Raymond, C. Rosen, and Y.E. Shi, Molecular
cloning and characterization of human tissue inhibitor of metalloproteinase 4.
J.Biol.Chem., 1996. 271(48): p. 30375-30380.

83.

Morgunova, E., A. Tuuttila, U. Bergmann, M. Isupov, Y. Lindqvist, G. Schneider, and K.
Tryggvason, Structure of human pro-matrix metalloproteinase-2: activation mechanism
revealed. Science, 1999. 284(5420): p. 1667-70.

84.

Ogata, T., H. Shibamura, G. Tromp, M. Sinha, K.A. Goddard, N. Sakalihasan, R. Limet,
G.L. MacKean, C. Arthur, T. Sueda, S. Land, and H. Kuivaniemi, Genetic analysis of
polymorphisms in biologically relevant candidate genes in patients with abdominal aortic
aneurysms. J Vasc Surg, 2005. 41(6): p. 1036-42.
105

85.

Wang, X., G. Tromp, C.W. Cole, A. Verloes, N. Sakalihasan, S. Yoon, and H.
Kuivaniemi, Analysis of coding sequences for tissue inhibitor of metalloproteinases 1
(TIMP1) and 2 (TIMP2) in patients with aneurysms. Matrix Biol, 1999. 18(2): p. 121-4.

86.

Hinterseher, I., D. Krex, E. Kuhlisch, K.G. Schmidt, C. Pilarsky, W. Schneiders, H.D.
Saeger, and H. Bergert, Tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphisms
in a Caucasian population with abdominal aortic aneurysm. World J Surg, 2007. 31(11):
p. 2248-54.

87.

Luger, K., A.W. Mader, R.K. Richmond, D.F. Sargent, and T.J. Richmond, Crystal
structure of the nucleosome core particle at 2.8 A resolution. Nature, 1997. 389(6648): p.
251-60.

88.

Goldberg, A.D., C.D. Allis, and E. Bernstein, Epigenetics: a landscape takes shape. Cell,
2007. 128(4): p. 635-8.

89.

Egger, G., G. Liang, A. Aparicio, and P.A. Jones, Epigenetics in human disease and
prospects for epigenetic therapy. Nature, 2004. 429(6990): p. 457-63.

90.

Choi, S.W. and S. Friso, Epigenetics: A New Bridge between Nutrition and Health. Adv
Nutr, 2010. 1(1): p. 8-16.

91.

Hunter, R.G., Epigenetic effects of stress and corticosteroids in the brain. Front Cell
Neurosci, 2012. 6: p. 18.

92.

De Prins, S., G. Koppen, G. Jacobs, E. Dons, E. Van de Mieroop, V. Nelen, F. Fierens, L.
Int Panis, P. De Boever, B. Cox, T.S. Nawrot, and G. Schoeters, Influence of ambient air
pollution on global DNA methylation in healthy adults: a seasonal follow-up. Environ
Int, 2013. 59: p. 418-24.

93.

Johnson, T.B. and R.D. Coghill, Researches on Pyrimidines. C111. The Discovery of 5Methyl-Cytosine in Tuberculinic Acid, the Nucleic Acid of the Tubercle Bacillus1. Journal
of the American Chemical Society, 1925. 47(11): p. 2838-2844.

94.

Bernstein, B.E., A. Meissner, and E.S. Lander, The mammalian epigenome. Cell, 2007.
128(4): p. 669-81.

106

95.

Miranda, T.B. and P.A. Jones, DNA methylation: the nuts and bolts of repression. Journal
of cellular physiology, 2007. 213(2): p. 384-90.

96.

Haines, T.R., D.I. Rodenhiser, and P.J. Ainsworth, Allele-specific non-CpG methylation
of the Nf1 gene during early mouse development. Developmental biology, 2001. 240(2):
p. 585-98.

97.

Prokhortchouk, A., B. Hendrich, H. Jorgensen, A. Ruzov, M. Wilm, G. Georgiev, A.
Bird, and E. Prokhortchouk, The p120 catenin partner Kaiso is a DNA methylationdependent transcriptional repressor. Genes Dev, 2001. 15(13): p. 1613-8.

98.

Jenuwein, T. and C.D. Allis, Translating the histone code. Science, 2001. 293(5532): p.
1074-80.

99.

McKinsey, T.A., C.L. Zhang, and E.N. Olson, Control of muscle development by dueling
HATs and HDACs. Curr Opin Genet Dev, 2001. 11(5): p. 497-504.

100.

Narlikar, G.J., H.Y. Fan, and R.E. Kingston, Cooperation between complexes that
regulate chromatin structure and transcription. Cell, 2002. 108(4): p. 475-87.

101.

Pons, D. and J.W. Jukema, Epigenetic histone acetylation modifiers in vascular
remodelling - new targets for therapy in cardiovascular disease. Neth Heart J, 2008.
16(1): p. 30-2.

102.

Ha, C.H., W. Wang, B.S. Jhun, C. Wong, A. Hausser, K. Pfizenmaier, T.A. McKinsey,
E.N. Olson, and Z.G. Jin, Protein kinase D-dependent phosphorylation and nuclear
export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene
expression and angiogenesis. J Biol Chem, 2008. 283(21): p. 14590-9.

103.

Wang, S., X. Li, M. Parra, E. Verdin, R. Bassel-Duby, and E.N. Olson, Control of
endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7.
Proc Natl Acad Sci U S A, 2008. 105(22): p. 7738-43.

104.

Bannister, A.J. and T. Kouzarides, Reversing histone methylation. Nature, 2005.
436(7054): p. 1103-6.

107

105.

Austin, R.C., S.R. Lentz, and G.H. Werstuck, Role of hyperhomocysteinemia in
endothelial dysfunction and atherothrombotic disease. Cell Death.Differ., 2004. 11
Suppl 1: p. S56-S64.

106.

Refsum, H., A.D. Smith, P.M. Ueland, E. Nexo, R. Clarke, J. McPartlin, C. Johnston, F.
Engbaek, J. Schneede, C. McPartlin, and J.M. Scott, Facts and recommendations about
total homocysteine determinations: an expert opinion. Clin.Chem., 2004. 50(1): p. 3-32.

107.

Mendis, S., S.B. Athauda, M. Naser, and K. Takahashi, Association between
hyperhomocysteinaemia and hypertension in Sri Lankans. J Int Med Res, 1999. 27(1): p.
38-44.

108.

Lim, U. and P.A. Cassano, Homocysteine and blood pressure in the Third National
Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol, 2002. 156(12):
p. 1105-13.

109.

Law, J.A. and S.E. Jacobsen, Establishing, maintaining and modifying DNA methylation
patterns in plants and animals. Nat.Rev.Genet., 2010. 11(3): p. 204-220.

110.

Berger, J. and A. Bird, Role of MBD2 in gene regulation and tumorigenesis.
Biochem.Soc.Trans., 2005. 33(Pt 6): p. 1537-1540.

111.

Kouzarides, T., Histone methylation in transcriptional control. Curr.Opin.Genet.Dev.,
2002. 12(2): p. 198-209.

112.

Yideng, J., Z. Jianzhong, H. Ying, S. Juan, Z. Jinge, W. Shenglan, H. Xiaoqun, and W.
Shuren, Homocysteine-mediated expression of SAHH, DNMTs, MBD2, and DNA
hypomethylation potential pathogenic mechanism in VSMCs. DNA Cell Biol., 2007.
26(8): p. 603-611.

113.

Amarnath, K., V. Amarnath, K. Amarnath, H.L. Valentine, and W.M. Valentine, A
specific HPLC-UV method for the determination of cysteine and related aminothiols in
biological samples. Talanta, 2003. 60(6): p. 1229-38.

114.

Sen, U., P. Basu, O.A. Abe, S. Givvimani, N. Tyagi, N. Metreveli, K.S. Shah, J.C.
Passmore, and S.C. Tyagi, Hydrogen sulfide ameliorates hyperhomocysteinemiaassociated chronic renal failure. Am J Physiol Renal Physiol, 2009. 297(2): p. F410-9.
108

115.

Sen, U., N. Tyagi, M. Kumar, K.S. Moshal, W.E. Rodriguez, and S.C. Tyagi,
Cystathionine-beta-synthase gene transfer and 3-deazaadenosine ameliorate
inflammatory response in endothelial cells. Am J Physiol Cell Physiol, 2007. 293(6): p.
C1779-87.

116.

Dai, X.D., M. Yin, W. Jing, H.Q. DU, H.Y. Ye, Y.J. Shang, L. Zhang, Y.Y. Zou, Z.P.
Qu, and J. Pan, [Expressions of atherosclerosis-related genes in aorta in young
apoE/LDLR double knockout mice.]. Sheng Li Xue.Bao., 2008. 60(1): p. 43-50.

117.

Untergasser, A., I. Cutcutache, T. Koressaar, J. Ye, B.C. Faircloth, M. Remm, and S.G.
Rozen, Primer3--new capabilities and interfaces. Nucleic Acids Res, 2012. 40(15): p.
e115.

118.

Takagi, H. and T. Umemoto, Homocysteinemia is a risk factor for aortic dissection.
Med.Hypotheses, 2005. 64(5): p. 1007-1010.

119.

Moroz, P., M.T. Le, and P.E. Norman, Homocysteine and abdominal aortic aneurysms.
ANZ.J.Surg., 2007. 77(5): p. 329-332.

120.

Riba, R., A. Nicolaou, M. Troxler, S. Homer-Vaniasinkam, and K.M. Naseem, Altered
platelet reactivity in peripheral vascular disease complicated with elevated plasma
homocysteine levels. Atherosclerosis, 2004. 175(1): p. 69-75.

121.

Schroecksnadel, K., B. Frick, C. Winkler, F. Leblhuber, B. Wirleitner, and D. Fuchs,
Hyperhomocysteinemia and immune activation. Clin Chem Lab Med, 2003. 41(11): p.
1438-43.

122.

Yideng, J., Z. Jianzhong, H. Ying, S. Juan, Z. Jinge, W. Shenglan, H. Xiaoqun, and W.
Shuren, Homocysteine-mediated expression of SAHH, DNMTs, MBD2, and DNA
hypomethylation potential pathogenic mechanism in VSMCs. DNA Cell Biol, 2007.
26(8): p. 603-11.

123.

Graham, I.M., L.E. Daly, H.M. Refsum, K. Robinson, L.E. Brattstrom, P.M. Ueland, R.J.
Palma-Reis, G.H. Boers, R.G. Sheahan, B. Israelsson, C.S. Uiterwaal, R. Meleady, D.
McMaster, P. Verhoef, J. Witteman, P. Rubba, H. Bellet, J.C. Wautrecht, H.W. de Valk,
A.C. Sales Luis, F.M. Parrot-Rouland, K.S. Tan, I. Higgins, D. Garcon, G. Andria, and et
109

al., Plasma homocysteine as a risk factor for vascular disease. The European Concerted
Action Project. JAMA, 1997. 277(22): p. 1775-81.
124.

Majors, A., L.A. Ehrhart, and E.H. Pezacka, Homocysteine as a risk factor for vascular
disease. Enhanced collagen production and accumulation by smooth muscle cells.
Arterioscler Thromb Vasc Biol, 1997. 17(10): p. 2074-81.

125.

Chen, N.C., F. Yang, L.M. Capecci, Z. Gu, A.I. Schafer, W. Durante, X.F. Yang, and H.
Wang, Regulation of homocysteine metabolism and methylation in human and mouse
tissues. FASEB J, 2010. 24(8): p. 2804-17.

126.

Lin, X.H., C. Guo, L.J. Gu, and T.F. Deuel, Site-specific methylation inhibits
transcriptional activity of platelet-derived growth factor A-chain promoter. J Biol Chem,
1993. 268(23): p. 17334-40.

127.

Alexander, M.R. and G.K. Owens, Epigenetic control of smooth muscle cell
differentiation and phenotypic switching in vascular development and disease. Annu Rev
Physiol, 2012. 74: p. 13-40.

128.

Ross, R., Growth regulatory mechanisms and formation of the lesions of atherosclerosis.
Ann N Y Acad Sci, 1995. 748: p. 1-4; discussion 4-6.

129.

Ross, R., Cell biology of atherosclerosis. Annu Rev Physiol, 1995. 57: p. 791-804.

130.

Evanko, S.P., E.W. Raines, R. Ross, L.I. Gold, and T.N. Wight, Proteoglycan
distribution in lesions of atherosclerosis depends on lesion severity, structural
characteristics, and the proximity of platelet-derived growth factor and transforming
growth factor-beta. Am J Pathol, 1998. 152(2): p. 533-46.

131.

Royce, P.M. and M.J. Barnes, Failure of highly purified lysyl hydroxylase to hydroxylate
lysyl residues in the non-helical regions of collagen. Biochem J, 1985. 230(2): p. 475-80.

132.

Kumar, M., N. Tyagi, K.S. Moshal, U. Sen, S. Kundu, P.K. Mishra, S. Givvimani, and
S.C. Tyagi, Homocysteine decreases blood flow to the brain due to vascular resistance in
carotid artery. Neurochem.Int., 2008. 53(6-8): p. 214-219.

133.

Choumenkovitch, S.F., J. Selhub, P.J. Bagley, N. Maeda, M.R. Nadeau, D.E. Smith, and
S.W. Choi, In the cystathionine beta-synthase knockout mouse, elevations in total plasma
110

homocysteine increase tissue S-adenosylhomocysteine, but responses of Sadenosylmethionine and DNA methylation are tissue specific. J.Nutr., 2002. 132(8): p.
2157-2160.
134.

Kinoshita, M., S. Numata, A. Tajima, S. Shimodera, I. Imoto, and T. Ohmori, Plasma
total homocysteine is associated with DNA methylation in patients with schizophrenia.
Epigenetics, 2013. 8(6): p. 584-90.

135.

Jain, D., E.K. Fishman, P. Argani, A.S. Shah, and M.K. Halushka, Unexpected sclerosing
mediastinitis involving the ascending aorta in the setting of a multifocal fibrosclerotic
disorder. Pathol Res Pract, 2011. 207(1): p. 60-2.

136.

Puranik, R., C.K. Chow, J.A. Duflou, M.J. Kilborn, and M.A. McGuire, Sudden death in
the young. Heart Rhythm, 2005. 2(12): p. 1277-82.

137.

Nishimura, R.A., Cardiology patient pages. Aortic valve disease. Circulation, 2002.
106(7): p. 770-2.

138.

Moroz, P., M.T. Le, and P.E. Norman, Homocysteine and abdominal aortic aneurysms.
ANZ J Surg, 2007. 77(5): p. 329-32.

139.

Guthikonda, S. and W.G. Haynes, Homocysteine: role and implications in
atherosclerosis. Curr Atheroscler Rep, 2006. 8(2): p. 100-6.

140.

Sundstrom, J., L. Sullivan, R.B. D'Agostino, P.F. Jacques, J. Selhub, I.H. Rosenberg,
P.W. Wilson, D. Levy, and R.S. Vasan, Plasma homocysteine, hypertension incidence,
and blood pressure tracking: the Framingham Heart Study. Hypertension, 2003. 42(6): p.
1100-5.

141.

Ovechkin, A.V., N. Tyagi, U. Sen, D. Lominadze, M.M. Steed, K.S. Moshal, and S.C.
Tyagi, 3-Deazaadenosine mitigates arterial remodeling and hypertension in
hyperhomocysteinemic mice. Am J Physiol Lung Cell Mol Physiol, 2006. 291(5): p.
L905-11.

142.

Tyagi, S.C., L. Matsubara, and K.T. Weber, Direct extraction and estimation of
collagenase(s) activity by zymography in microquantities of rat myocardium and uterus.
Clin Biochem, 1993. 26(3): p. 191-8.
111

143.

Mareckova, Z., S. Heller, and K. Horky, [Endothelial dysfunction and arterial
hypertension]. Vnitr Lek, 1999. 45(4): p. 232-7.

144.

Li, N., F.X. Yi, E. Rute, D.X. Zhang, G.R. Slocum, and A.P. Zou, Effects of
homocysteine on intracellular nitric oxide and superoxide levels in the renal arterial
endothelium. Am J Physiol Heart Circ Physiol, 2002. 283(3): p. H1237-43.

145.

Ungvari, Z., A. Csiszar, Z. Bagi, and A. Koller, Impaired nitric oxide-mediated flowinduced coronary dilation in hyperhomocysteinemia: morphological and functional
evidence for increased peroxynitrite formation. Am J Pathol, 2002. 161(1): p. 145-53.

146.

Topal, G., A. Brunet, E. Millanvoye, J.L. Boucher, F. Rendu, M.A. Devynck, and M.
David-Dufilho, Homocysteine induces oxidative stress by uncoupling of NO synthase
activity through reduction of tetrahydrobiopterin. Free Radic Biol Med, 2004. 36(12): p.
1532-41.

147.

Sander, M., B. Chavoshan, and R.G. Victor, A large blood pressure-raising effect of
nitric oxide synthase inhibition in humans. Hypertension, 1999. 33(4): p. 937-42.

148.

Juonala, M., J.S. Viikari, T. Ronnemaa, H. Helenius, L. Taittonen, and O.T. Raitakari,
Elevated blood pressure in adolescent boys predicts endothelial dysfunction: the
cardiovascular risk in young Finns study. Hypertension, 2006. 48(3): p. 424-30.

149.

Selhub, J., Homocysteine metabolism. Annu Rev Nutr, 1999. 19: p. 217-46.

150.

Mizuno, S., T. Chijiwa, T. Okamura, K. Akashi, Y. Fukumaki, Y. Niho, and H. Sasaki,
Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and
in acute and chronic myelogenous leukemia. Blood, 2001. 97(5): p. 1172-9.

151.

Heyn, H. and M. Esteller, DNA methylation profiling in the clinic: applications and
challenges. Nat Rev Genet, 2012. 13(10): p. 679-92.

152.

Sen, U., W.E. Rodriguez, N. Tyagi, M. Kumar, S. Kundu, and S.C. Tyagi, Ciglitazone, a
PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine
clearance. Am J Physiol Endocrinol Metab, 2008. 295(5): p. E1205-12.

153.

Pushpakumar, S., S. Kundu, T. Pryor, S. Givvimani, E. Lederer, S.C. Tyagi, and U. Sen,
Angiotensin-II induced hypertension and renovascular remodelling in tissue inhibitor of
112

metalloproteinase 2 knockout mice. J Hypertens, 2013. 31(11): p. 2270-81; discussion
2281.
154.

Giusti, B., R. Marcucci, I. Lapini, I. Sestini, M. Lenti, M. Yacoub, and G. Pepe, Role of
hyperhomocysteinemia in aortic disease. Cell Mol Biol (Noisy-le-grand), 2004. 50(8): p.
945-52.

155.

Takagi, H. and T. Umemoto, Homocysteinemia is a risk factor for aortic dissection. Med
Hypotheses, 2005. 64(5): p. 1007-10.

156.

Tribouilloy, C.M., M. Peltier, M.C. Iannetta Peltier, F. Trojette, M. Andrejak, and J.P.
Lesbre, Plasma homocysteine and severity of thoracic aortic atherosclerosis. Chest,
2000. 118(6): p. 1685-9.

157.

Novaro, G.M., H.D. Aronow, E. Mayer-Sabik, and B.P. Griffin, Plasma homocysteine
and calcific aortic valve disease. Heart, 2004. 90(7): p. 802-3.

158.

Chicoine, E., P.O. Esteve, O. Robledo, C. Van Themsche, E.F. Potworowski, and Y. StPierre, Evidence for the role of promoter methylation in the regulation of MMP-9 gene
expression. Biochem Biophys Res Commun, 2002. 297(4): p. 765-72.

159.

Zaina, S., M.W. Lindholm, and G. Lund, Nutrition and aberrant DNA methylation
patterns in atherosclerosis: more than just hyperhomocysteinemia? J Nutr, 2005. 135(1):
p. 5-8.

160.

Gupta, S. and W.D. Kruger, Cystathionine beta-synthase deficiency causes fat loss in
mice. PLoS One, 2011. 6(11): p. e27598.

161.

Tsai, J.C., H.T. Kuo, Y.W. Chiu, S.J. Hwang, H.Y. Chuang, J.M. Chang, H.C. Chen, and
Y.H. Lai, Correlation of plasma homocysteine level with arterial stiffness and pulse
pressure in hemodialysis patients. Atherosclerosis, 2005. 182(1): p. 121-7.

162.

Vermeulen, E.G., C.D. Stehouwer, J.W. Twisk, M. van den Berg, S.C. de Jong, A.J.
Mackaay, C.M. van Campen, F.C. Visser, C.A. Jakobs, E.J. Bulterjis, and J.A. Rauwerda,
Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression
of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet, 2000.
355(9203): p. 517-22.
113

163.

Wang, X., B. Falkner, H. Zhu, H. Shi, S. Su, X. Xu, A.K. Sharma, Y. Dong, F. Treiber,
B. Gutin, G. Harshfield, and H. Snieder, A genome-wide methylation study on essential
hypertension in young African American males. PLoS One, 2013. 8(1): p. e53938.

164.

Reddy, H.K., S.K. Koshy, S. Wasson, E.E. Quan, S. Pagni, A.M. Roberts, I.G. Joshua,
and S.C. Tyagi, Adaptive-outward and maladaptive-inward arterial remodeling
measured by intravascular ultrasound in hyperhomocysteinemia and diabetes. J
Cardiovasc Pharmacol Ther, 2006. 11(1): p. 65-76.

165.

Frauchiger, B., H.P. Schmid, C. Roedel, P. Moosmann, and D. Staub, Comparison of
carotid arterial resistive indices with intima-media thickness as sonographic markers of
atherosclerosis. Stroke, 2001. 32(4): p. 836-41.

166.

Bednarek, N., P. Svedin, R. Garnotel, G. Favrais, G. Loron, L. Schwendiman, H.
Hagberg, P. Morville, C. Mallard, and P. Gressens, Increased MMP-9 and TIMP-1 in
mouse neonatal brain and plasma and in human neonatal plasma after hypoxiaischemia: a potential marker of neonatal encephalopathy. Pediatr Res, 2012. 71(1): p.
63-70.

167.

Koullias, G.J., P. Ravichandran, D.P. Korkolis, D.L. Rimm, and J.A. Elefteriades,
Increased tissue microarray matrix metalloproteinase expression favors proteolysis in
thoracic aortic aneurysms and dissections. Ann Thorac Surg, 2004. 78(6): p. 2106-10;
discussion 2110-1.

168.

Powers, R.W., R.E. Gandley, D.L. Lykins, and J.M. Roberts, Moderate
hyperhomocysteinemia decreases endothelial-dependent vasorelaxation in pregnant but
not nonpregnant mice. Hypertension, 2004. 44(3): p. 327-33.

169.

Hucks, D., R.C. Thuraisingham, M.J. Raftery, and M.M. Yaqoob, Homocysteine induced
impairment of nitric oxide-dependent vasorelaxation is reversible by the superoxide
dismutase mimetic TEMPOL. Nephrol Dial Transplant, 2004. 19(8): p. 1999-2005.

170.

Tyagi, N., N. Qipshidze, U. Sen, W. Rodriguez, A. Ovechkin, and S.C. Tyagi,
Cystathionine beta synthase gene dose dependent vascular remodeling in murine model
of hyperhomocysteinemia. Int J Physiol Pathophysiol Pharmacol, 2011. 3(3): p. 210-22.

114

171.

Finkelstein, J.D. and J.J. Martin, Methionine metabolism in mammals. Distribution of
homocysteine between competing pathways. J Biol Chem, 1984. 259(15): p. 9508-13.

172.

Kraus, J.P., M. Janosik, V. Kozich, R. Mandell, V. Shih, M.P. Sperandeo, G. Sebastio, R.
de Franchis, G. Andria, L.A. Kluijtmans, H. Blom, G.H. Boers, R.B. Gordon, P.
Kamoun, M.Y. Tsai, W.D. Kruger, H.G. Koch, T. Ohura, and M. Gaustadnes,
Cystathionine beta-synthase mutations in homocystinuria. Hum Mutat, 1999. 13(5): p.
362-75.

173.

Tang, B., A. Mustafa, S. Gupta, S. Melnyk, S.J. James, and W.D. Kruger, Methioninedeficient diet induces post-transcriptional downregulation of cystathionine beta-synthase.
Nutrition, 2010. 26(11-12): p. 1170-5.

174.

Chen, W., J.X. Guo, and P. Chang, The effect of taurine on cholesterol metabolism. Mol
Nutr Food Res, 2012. 56(5): p. 681-90.

175.

Bonsch, D., B. Lenz, U. Reulbach, J. Kornhuber, and S. Bleich, Homocysteine associated
genomic DNA hypermethylation in patients with chronic alcoholism. J Neural Transm,
2004. 111(12): p. 1611-6.

176.

Rampersaud, G.C., G.P. Kauwell, A.D. Hutson, J.J. Cerda, and L.B. Bailey, Genomic
DNA methylation decreases in response to moderate folate depletion in elderly women.
Am J Clin Nutr, 2000. 72(4): p. 998-1003.

177.

Zhang, J.G., J.X. Liu, Z.H. Li, L.Z. Wang, Y.D. Jiang, and S.R. Wang, Dysfunction of
endothelial NO system originated from homocysteine-induced aberrant methylation
pattern in promoter region of DDAH2 gene. Chin Med J (Engl), 2007. 120(23): p. 21327.

178.

Krishna, S.M., A. Dear, J.M. Craig, P.E. Norman, and J. Golledge, The potential role of
homocysteine mediated DNA methylation and associated epigenetic changes in
abdominal aortic aneurysm formation. Atherosclerosis, 2013. 228(2): p. 295-305.

115

LIST OF ABBREVIATIONS
5-mC – 5-methylcytosine
AAA - Abdominal aortic aneurysm
Ach – Acetylcholine
ANOVA – Analysis of variance
Aza – 5-Aza-2’-deoxycytidine
BHMT – Betaine homocysteine methyltransferase
BP – Blood pressure
CBS – Cystathionine beta synthase
CDC – Center for disease control and prevention
CMN – Cystic medial necrosis
Col - Collagen
Ctrl - Control
CVD – Cardiovascular disease
DDAH – Dimethylarginine dimethylaminohydrolase
DMEM – Dulbecco’s modified eagle medium
DNMT – DNA methyltransferase
116

ECM – Extracellular matrix
EDV – End diastolic velocity
ELISA – Enzyme-linked immunosorbent assay
FDA – Food and drug administration
GAPDH – Glyceraldehyde 3-phosphate dehydrogenase
H3K9me3 - Histone 3 trimethylated at lysine 9 residue
HAT – Histone acetyl transferase
Hcy – Homocysteine
HDAC – Histone deacetylase
HDM – Histone demethylase
HHcy – Hyperhomocysteinemia
HMT – Histone methyltransferase
HPLC-UV – High performance liquid chromatography with UV detector
HRP – Horseradish peroxidase
IHC - Immunohistochemistry
MBD - Methyl binding domain protein
MCP – Monocyte chemotactic protein
117

MDS – Myelodysplastic syndrome
MFS – Marfan syndrome
MMP – Matrix metalloproteinase
MS – Methionine synthase
MTHFR - 5,10 methylene tetrahydrofolate reductase
NO – Nitric oxide
PBS – Phosphate buffer saline
Phe – Phenylephrine
PSV – Peak systolic velocity
RI – Resistive index
ROS – Reactive oxygen species
RT-PCR – Reverse transcription polymerase chain reaction
SAHH – S-adenosyl homocysteine hydrolase
SAM – S-adenosyl methionine
SAH – S-adenosyl homocysteine
SEM – Standard error of mean
SMC – Smooth muscle cells
118

SNP – Sodium nitroprusside
SULF1 – Sulfatase 1
TAA - Thoracic aortic aneurysm
THF - Tetrahydrofolate
TIMP – Tissue inhibitor of metalloproteinase
VSMC – Vascular smooth muscle cells
WT - Wild type

119

CURRICULUM VITAE

Name :

Nithya Narayanan

Address :

627 S Preston Street 7K, Louisville, KY 40202

E-mail :

nithyanar@hotmail.com

EDUCATION
B.Tech. Department of Biotechnology
Anna University, Chennai, India
Percentage: 83.5% (Secured among top 10 ranks in the class)

2005 - 2009

M.S., Department of Molecular and Cell Biology
University of Texas at Dallas (UTD), Richardson, TX
GPA: 3.45

2009 - 2011

PhD, Department of Physiology and Biophysics

2011 – 2014

University of Louisville Medical School, Louisville, KY
GPA: 3.85

RESEARCH EXPERIENCE
Epigenetic regulation of aortic remodeling in hyperhomocysteinemia
University of Louisville, Louisville, KY
Working with Dr. Suresh C.Tyagi

Jun’11 – May’14

Analysis of Nitric Oxide (NO) stress on Uropathogenic strains of E.coli
University of Texas at Dallas (UTD), Richardson, TX
Worked with Dr. Stephen Spiro

Aug ‘10 – May ‘11

Learned Python and its applications in Bioinformatics
University of Texas at Dallas (UTD), Richardson, TX
Worked with Dr. Micheal Zhang

May ‘10 – Aug ‘10

Research study on assaying enzymes involved in metabolic pathways in ytfE mutants of
E.coli
University of Texas at Dallas (UTD), Richardson, TX
Jan ‘10 – May ‘10
Worked with Dr. Stephen Spiro
Phylogenetic analysis of cDNA of RNA polymerase in Physarum and Fuligo
University of Texas at Dallas (UTD), Richardson, TX
Aug ‘09 – Dec ‘09
Worked with Dr. Dennis Miller
120

Practical Summer Training Course on Molecular Biology Techniques (PCMB)
Vellore Institute of Technology (VIT), Vellore, India
May ‘09 – June ‘09
Expression and Purification of potyvirus like particles (PVLP) from E.coli
Mepco Schlenk Engineering College, Sivakasi (Affiliated to Anna University), India
Worked with Dr. Stephen Raj
Jan ‘09 – May ‘09
Training program in Genomics
Sai Biosciences Research Institute (SBRI), Chennai, India

June ‘08

TEACHING EXPERIENCE
Teaching Assistant for “Human Anatomy and Physiology II Lab (BIOL 3456)”
Worked with Dr. Wen Yu
May ’10 - Aug ‘10
Teaching Assistant for “Classical and Molecular Genetics (BIOL 3301)”
Worked with Dr. Jeff DeJong and Dr. Dennis Miller

Jan ‘10 – May ‘10

Assisted in training students for summer research program and Louisville Regional Science Fair
2012 - 2014

MEMBERSHIPS IN PROFESSIONAL AND HONORARY SOCIETIES





Student member, American Physiological Society
Member,American Association for the Advancement of Science (AAAS)
Secretary, Toastmasters International Club #7458 (2013-2014)
Secretary, Enlighten Charity Inc.

AWARDS AND HONORS





Received Graduate Dean’s Citation award, 2014
Received consolation award for best oral presentation at Trainees of Physiological
Genomics session, Experimental Biology, 2012
Received travel award from Department of Physiology and Biophysics, University of
Louisville to attend Experimental Biology 2012-2014
Received travel award from School of Medicine, University of Louisville to attend
Experimental Biology 2012-2014

 Received GSC travel funding to attend Experimental Biology, 2012 and 2014
EXTRA CURRICULAR ACTIVITIES




Judge, Louisville Regional Science Fair 2013-2014
Volunteer, TEDx Louisville, 2012
Volunteer, Career Fair, University of Texas at Dallas 2012-2013
121

MANUSCRIPTS PUBLISHED












Givvimani, S, Munjal, C, Narayanan, N, Aqil, F, Tyagi, G, Metreveli, N, Tyagi, S. C,
Givvimani, S., Hyperhomocysteinemia decreases intestinal motility leading to
constipation. Am J Physiol Gastrointest Liver Physiol, 2012. 303(3): p. G281-90
Givvimani, S., Narayanan, N., Armaghan, F., Pushpakumar, S.Tyagi, S. C., Attenuation
of conducted vasodilation in skeletal muscle arterioles during hyperhomocysteinemia.
Pharmacology, 2013. 91 (5-6): p. 287-96
Givvimani, S, Kundu, S, Narayanan, N, Armaghan, F, Qipshidze, N, Pushpakumar, S,
Vacek, T. P, Tyagi, S. C TIMP-2 mutant decreases MMP-2 activity and augments
pressure overload induced LV dysfunction and heart failure. Arch Physiol Biochem,
2013. 119(2): p. 65-74
Narayanan, N., Tyagi, N., Shah, A., Pagni,S., Tyagi, S. C. Hyperhomocysteinemia
during aortic aneurysm, a plausible role of epigenetics. Int J Physiol Pathophysiol
Pharmacol, 2013. 5(1): p. 32-42
Givvimani S, Narayanan N, Pushpakumar SB, C Tyagi S. Anti-Parstatin Promotes
Angiogenesis and Ameliorates Left Ventricular Dysfunction during Pressure Overload
Int J Biomed Sci. 2014 Mar;10(1):1-7

Nithya Narayanan, Sathnur Basappa Pushpakumar, Srikanth Givvimani, Sourav
Kundu, Naira Metreveli, Dexter James, Adrienne P. Bratcher, Suresh C. Tyagi
Epigenetic Regulation of Aortic Remodeling in Hyperhomocysteinemia FASEB J.
2014 Apr 16

MANUSCRIPTS IN PREPARATION


Nithya Narayanan, Sourav Kundu, Srikanth Givvimani, Sathnur B Pushpakumar,
Ruhi Kulkarni, Suresh C Tyagi Global DNA Methylation and Extracellular Matrix
Remodeling in Aortic Smooth Muscle versus Endothelial Cells in
Hyperhomocysteinemia
In preparation

CONFERENCE ABSTRACT PRESENTATIONS





Nithya Narayanan, Neetu Tyagi, Sebastian Pagni and Suresh C. Tyagi Epigenetic
mechanism of atherosclerosis and hypertension in Hyperhomocysteinemia FASEBJ
March 2012
(selected for oral and poster presentation)
Tyagi N, Narayanan N,Givvimani S,Tyagi SC Bad to Bone: Homocysteine FASEB
J March 29, 2012 26:1143.5
Tyagi N, Narayanan N, Mishra PK,Qipshidze,N,Givvimani S,Tyagi SC Epigenetic
Reprogramming of Mitochondrial Dysfunction in hyperhomocysteinemia FASEB J
March 29, 2012 26:701.17

122

















Givvimani S, Narayanan N, Armaghan F, Pushpakumar S and Tyagi SC Attenuation
of conducted vasodilation in skeletal muscle arterioles during hyperhomocysteinemia
FASEBJ March 29 2012
Tyagi N, Qipshidze N, Narayanan N , Givvimani S, Tyagi SC. Hydrogen sulfide
mitigates cerebro-vascular remodeling during cerebral ischemia. Society of
Neuroscience, 2012,New Orleans
Srikanth Givvimani, Anuradha Kalani, Nithya Narayanan, Sourav Kundu, Suresh
Tyagi, Micro RNA-499 Protects the Heart Against Adverse Post Myocardial
Infarction Remodeling and Regenerates Damaged Myocardium by Promoting
Endogenous Cardiac Stem Cell Differentiation, HBPR 2013
N.Narayanan, S.B. Pushpakumar, N. Qipshidze, A.P. Bratcher, N. Tyagi and S.C.
Tyagi Epigenetic inhibition by 5 Aza 2’ deoxycytidine mitigates hypertension in
hyperhomocysteinemia FASEBJ 2013 955.9
S. Givvimani, N. Narayanan, S.B. Pushpakumar and S.C. Tyagi Anti-parstatin
promotes angiogenesis and ameliorates left ventricular dysfunction during pressure
overload. FASEBJ 2013 1129.16
A. Kalani, N. Narayanan, N. Qipshidze, S. Givvimani, P.K. Kamat, S.C. Tyagi and
N. Tyagi. Epigenetic regulation of cerebrovascular remodeling mediated through
exosomes in hyperhomocysteinemia: role of folic acid. 932.9
Dexter James ,Nithya Narayanan,Adrienne Bratcher, Christina Roberts ,Suresh
Tyagi, Irving Joshua Aortic Vascular Responsiveness in Hyperhomocysteinemic Mice
Research Louisville 2013
Nithya Narayanan, Sourav Kundu, Srikanth Givvimani, Sathnur B Pushpakumar,
Ruhi Kulkarni, Suresh C Tyagi Global DNA Methylation and Extracellular Matrix
Remodeling in Aortic Smooth Muscle versus Endothelial Cells in
Hyperhomocysteinemia FASEBJ 2014
(selected for oral and poster presentation in Physiological Genomics Conference and
Epigenetics and Epigenomics session)

123

